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ABSTRACT  
Breast   cancer   is   the   most   common   cancer   in   women   worldwide.   To   date,  
diagnosis   and   metastasis   monitoring   are   mainly   carried   out   through   tissue  
biopsy,   a   very   invasive   procedure   limited   only   to   certain   locations   and   not  
always  feasible  in  clinical  practice.    Tumour  cells  release  DNA  into  the  blood  as  
circulating  cell-­free  DNA  (cfDNA),  which  can  be  sampled  from  circulating  blood,  
an  approach  known  as   liquid  biopsy.  This  provides  a   resource   for  biomarkers  
that  could  allow  the  use  of  minimally  invasive  liquid  biopsies  for  cancer-­related  
research,  diagnostics,  prognostics,  and   targeted   therapy.  The   levels  of   cfDNA  
have   already   been   shown   to   be   higher   in   cancer   individuals   than   healthy  
individuals,   and   correlate   with   tumour   metastasis,   response   to   therapy   and  
recurrence.   Recent   technological   advances   have   enabled   the   identification   of  
both   genetic   and   epigenetic   aberrations   in   cfDNA   that   reflect   changes   also  
found   in   patients’   tumours.   The   host   group   performed   methylation   analysis  
using  the  Illumina  EPIC  Methylation  Array,  which  interrogated  CpG  dinucleotide  
methylation  at  over  850,000  DNA  sites.  A   total  of  3172  CpGs  showed  median  
methylation   differences   of  more   than   40%   between   tumour   and   buffy   coat   of  
patients  with  breast  cancer.  This  MRes  project  aimed  to  establish  methods  for  
detecting   these   methylation   changes   between   matched   tumour   samples   and  
leucocytes  of  breast  cancer  patients,  and  in  cfDNA  by  using  the  Fluidigm  48.48  
Access   Array   microfluidics   system   and   the   Illumina   MiSeq   sequencer.   This  
approach   provided   quantitative,   medium-­throughput   targeted  measurement   of  
DNA   methylation   at   single   nucleotide   resolution.   Finally,   bisulfite  
pyrosequencing   was   used   as   a   sensitive   validation   technique   for   detecting  
differences   in   CpG   methylation,   providing   a   set   of   potential   biomarkers   that  
could   be   reliably   detected  by   circulating   tumour  DNA-­based   tests.  Translating  
the   alterations   that   are   seen   in   the   primary   tumour   into   an   assay   that   is  
applicable   to   cfDNA   will   have   important   diagnostic   implications,   such   as  
monitoring  tumour  progression,  drug  response  and  disease  recurrence,  as  well  
as   the   early   detection   of   cancer,   which   could   ultimately   complement   or   even  
avoid  the  need  for  tumour  tissue  biopsies.   
Keywords:   cell-­free  DNA,  methylation,   breast   cancer,   Fluidigm  48.48  Access  
Array  microfluidics,  biomarkers  
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LAY  SUMMARY  
Breast   cancer   is   the   most   common   cancer   in   women   worldwide.   To   date,  
diagnosis  and  monitoring  is  mainly  carried  out  through  surgery  of  tissue  biopsy,  
a   very   invasive   procedure   limited   only   to   certain   locations   and   not   always  
feasible   in   clinical   practice.   Like  many   other   cells,   cancerous   cells   shed  DNA  
into   the   blood   as   cell-­free   DNA   (cfDNA).   These   molecules   can   be   easily  
sampled   from   circulating   blood,   an   approach   know   as   liquid   biopsy.   A   liquid  
biopsy  may  be  used  to  help  find  cancer  at  an  early  stage.  It  may  also  be  used  to  
help  plan  treatment  or  to  find  out  how  well  treatment  is  working  or  if  cancer  has  
come  back.  Being  able   to   take  multiple   samples  of   blood  over   time  may  also  
help   to   understand   what   kind   of   molecular   changes   are   taking   place   in   a  
tumour.  Tests  in  development  examine  these  bits  of  DNA,  finding  different  types  
of  alterations  serving  as  markers  for  specific  cancer  types.  This  project  aimed  to  
establish  methods  for  detection  of  specific  changes  in  primary  tumour  samples  
and  in  cfDNA  of  breast  cancer  patients.  Establishing  methods  that  could  make  
cancer  detection  so  painless  that  it  becomes  part  of  routine  check-­ups  will  have  
important  diagnostic  implications,  such  as  monitoring  tumour  progression,  drug  
response   and   disease   recurrence,   as   well   as   the   early   detection   of   cancer,  
which   could   ultimately   complement   or   even   avoid   the   need   for   tumour   tissue  
biopsies.        
 




Cancer   is   a   very   heterogeneous   disease   in   most   aspects,   including   its  
cellularity,   different   genetic   alterations   and   several   clinical   behaviors.   The  
combinatorial  origin,  the  heterogeneity  of  malignant  cells,  and  the  variable  host  
background   produce   multiple   tumour   subclasses.   Many   analytical   methods  
have   been   used   to   study   human   tumours   and   to   classify   them   into  
homogeneous   groups   that   can   predict   clinical   behavior.   Currently,   cancer  
classifications  are  mostly  based  on  clinical  and  histomorphologic   features   that  
only   partially   reflect   the   molecular   heterogeneity   of   the   tumour,   reducing   the  
probability   of   the   most   appropriate   diagnostic,   prognostic   and   therapeutic  
strategy  for  each  patient1.  Progress  in  cancer  genomics  research  over  the  past  
few  decades  has  revealed  that  cancer  is  driven  by  various  genomic  alterations.  
As   a   result   of   different   international   initiatives   such   as   The   Cancer   Genome  
Atlas  (TCGA)  or  the  International  Cancer  Genome  Consortium  (ICGC),  the  use  
of  next-­generation  sequencing  (NGS)  has  helped  define  the  genomic  landscape  
of  early  stage  cancers2.  In  breast  cancer,  these  studies  have  reported  the  high  
level   of   tumour   heterogeneity   between   patients   that   consists   of   several  
molecular  subsets,  which  are  driven  by  different  molecular  alterations3.    
Breast   cancer   emerges   by   a   multistep   process   which   involves   the  
transformation  of  normal  cells  via  the  steps  of  hyperplasia,  premalignant  change  
and  in  situ  carcinoma4.  Like  all  cancers,  breast  cancer  is  considered  to  result  in  
part   from  the  accumulation  of  multiple  genetic  alterations   leading   to  oncogene  
overexpression   and   tumour   suppressor   loss5.  Recently,   the   role   of   epigenetic  
changes   has   emerged   as   a   crucial   and   characteristic   mechanism   in   many  
cancer   types5.   Epigenetic   modifications   are   believed   to   occur   early   in  
carcinogenesis  and  precede  genetic  alterations6.  Changes   in  DNA  methylation  
have   been   recognized   as   one   of   the   most   common   molecular   alterations   in  
cancer   and   hypermethylation   of   gene-­promoter   regions   is   a   suggested  
mechanism  of   loss  of  gene  function.  For  instance,  in  primary  lung  carcinomas,  
the   inactivation   of   the   tumour   suppressor   gene  p167,   the   DNA   repair  
gene  MGMT8,  and   the  detoxifying  gene  GSTP19  by  promoter  hypermethylation  
have   been   well   described.   At   the   same   time   that   certain   CGIs   become  
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9 
hypermethylated,   the  degree  of  genomic  DNA  hypomethylation   increases  from  
the  benign  proliferations  to  the  invasive  cancers10.  
Molecular   understanding   of   breast   carcinogenesis   has   been   accumulated  
during   the   last   decades   but   has   hardly   been   translated   into   the   clinic   as  
strategies   for   early   detection   or   prevention   of   cancer.   Screening   for   breast  
cancer   by   mammography   is   well   known   to   reduce   mortality11.      However,   an  
alternative  DNA-­based  approach   for  early  detection  of  breast  cancer  might  be  
promising  since  DNA  extracted  from  the  patient’s  plasma,  serum  or  other  body  
fluids   could   be   easily   amplified   by   PCR   technology   and   is   potentially   more  
sensitive  than  current  tests.    
Epigenetic   alterations,   including   aberrant   DNA   methylation,   have   been  
implicated   in   abnormal   expression   patterns   of   different   tumours,   including  
breast  cancer.  DNA  methylation  is  a  reversible  chemical  alteration  of  DNA  that  
mostly  affects  cytosines  when  located  5’  to  a  guanosine.  CpG  dinucleotides  are  
not   randomly   distributed   throughout   the   genome12.  Rather   they   are   frequently  
clustered  into  CpG  islands,  regions  that  are  rich   in  CpG  sites  and  these  areas  
are   frequently   located  at   the  promoter   regions  of   the  coding  genes  present   in  
the  mammalian  genome,  where  they  modulate  gene  transcription13.  It  has  been  
increasingly  recognized  that  the  CpG  islands  of  a  large  number  of  genes,  which  
are  mostly  unmethylated   in  normal   tissues,  are  methylated   in  human  cancers,  
including   breast   cancer5.   Detection   of   promoter   CpG   island   hypermethylation  
offers   several   advantages   compared   to   other   DNA   alterations   in   cancer14.  
Methylated  DNA  can  be  detected  with  a  very  high  degree  of  specificity,  even  in  
the  presence  of  a  vast  excess  of  unmethylated  DNA.  MethyLight  technology  for  
instance   can   detect   a   single   hypermethylated   allele   against   a   background   of  
10.000   unmethylated   alleles15.   Methylated   DNA   from   patients   with   manifest  
breast  cancer  has  been  detected  in  blood  16  as  well  as  in  ductal  lavage  fluid17.  
Detection  of  DNA  methylation  in  blood  might  prove  to  be  useful  as  a  predictive  
marker  at  the  moment  of  primary  diagnosis  or  as  a  marker  for  early  detection  of  
relapse   of   disease.   Therefore,   analysis   of   epigenetic   alteration   is   a   potential  
approach  in  early  detection  of  breast  cancer18.    
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10 
1.1.  Breast  Cancer    
  
Breast  cancer  is  the  most  common  malignant  disease  and  the  leading  cause  of  
cancer  death  among   females,  expected   to  account   for  29%  of  all   new  cancer  
diagnoses   in   women19.   Even   though   breast   cancer   survival   in   the   UK   has  
doubled   in   the   last   40   years,   this   improvement   is   achieved   by   earlier   stage  
diagnosis20.  Detection  of  localized  breast  cancer  at  an  early  stage,  when  cancer  
cells   have   not   yet   invaded   neighboring   normal   tissue,   has   better   prognosis   and  
requires   less   severe   treatment  with  a   survival   rate  of   98%21.  However,   breast  
cancer   is   frequently  diagnosed  at   a   late   stage  after   tumour  metastasis,  which  
lowers   the   survival   rate   to   14%22   (Figure   1).   Thus,   the   identification   of    
indicators  characterizing  the  early  stages  of  formation  and  progression  of  breast  












Figure   1:   Five-­Year   Relative   Survival   (%)   by   Breast   Cancer   Stage   at   diagnosis   in  
adults  aged  15-­99,  Former  Anglia  Cancer  Network.  Five-­year  survival  for  female  breast  
cancer  shows  a  much  more  rapid  decrease  in  survival  between  Stages  I  and  IV.  Five-­year  
relative   survival   in   women   ranges   from   99%   at   Stage   I   to   15%   at   Stage   IV   for   patients  
diagnosed  during  2002-­2006  in  the  former  Anglia  Cancer  Network.  From:  Cancer  research  
UK24.  
  
There  are  several  different  types  of  breast  cancer,  which  can  occur  in  different  
parts   of   the   breast.   According   to   the   Wold   Health   organization   (WHO)  
classification,  breast  cancer  can  be  classified  up  to  21  distinct  histological  types  
on   the  basis  of  cell  morphology,  growth  and  architecture  patterns25.  The  most  
common   type   is   invasive   ductal   breast   carcinoma   (IDC)   of   no   special   type  
(NST),  which  comprises  all   tumours  without  the  specific  differentiating  features  
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that   characterize   the   other   categories   of   breast   cancers26.   IDC   represents  
approximatelly   60%   to   75   %   of   all   breast   cancers,   whereas   breast   cancer  
special  types  represent  25%.  This  minoritary  group  includes  the  classic  lobular  
inavasive   carcinoma,   as   well   as   mucinous,   tubular,   adenoid   cystic   and  
cribriform  carcinomas,  among  others27.   
  
Breast   cancer   is   often   divided   into   non-­invasive   breast   cancer   (carcinoma   in  
situ)   when   cancerous   cells   remain   in   a   specific   location   of   the   breast  without  
spreading   to   surrounding   tissue,   or   invasive   breast   cancer   if   cancerous   cells  
break   through   normal   breast   tissue   and   spread   to   other   parts   of   the   body  
through  the  bloodstream  and  lymph  nodes.  Other  less  common  types  of  breast  
cancer   include   invasive   (and  pre-­invasive)   lobular  breast  cancer,   inflammatory  
breast   cancer   and   Paget’s   disease   of   the   breast28.   Most   breast   cancers  
are  carcinomas  if  they  start  in  the  epithelial  cells  that  line  organs  and  tissues.  In  
fact,   breast   cancers   are   often   a   type   of   carcinoma   called  adenocarcinoma,  
which   starts   in   cells   that   make   glands   (glandular   tissue).   Breast  
adenocarcinomas   start   in   the   ducts   (the   milk   ducts)   or   the   lobules   (milk-­
producing  glands).  There  are  other  types  of  breast  cancers,  such  as  sarcomas,  
which  start  in  the  cells  of  the  muscle,  fat,  or  connective  tissue,  and  sometimes  a  
single  breast  tumour  can  be  a  combination  of  these  different  types29. 
Breast   cancer   can   also   be   classified   based   on   the   receptor   status,   which   is  
important  in  deciding  treatment  options.    Breast  cancer  cells  can  express  three  
different   receptors:  estrogen  receptor  (ER),  progesterone  receptor  (PR),  which  
are      both   endocrine   receptors,   or   epidermal   growth   factor   receptor   (HER2).  
Cancers   are   called   hormone   receptor-­positive   or   hormone   receptor-­negative  
based  on  whether  or  not  they  have  these  receptors,  and  classified  as:    
•   Endocrine  receptor-­positive  (estrogen  or  progesterone  receptors).  
•   HER2-­positive.  
•   Triple  positive:  positive  for  estrogen  receptors,  progesterone  receptors,  
and  HER2.  
•   Triple  negative:  not  positive  for  estrogen  receptors,  progesterone  
receptors,  and  HER2.  
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Currently,  cancers  are  being  classified   into  molecular  subgroups  based  on  the  
variability   in   treatment   reponse   and   prognosis   than   current   histological  
classifications.   For   instance,   gene   expression   patterns   have   allowed  
classification   of   breast   tumours   into   five   different  molecular   subtypes,   namely  
basal-­like,  ErbB2+,  normal  breast  like,  luminal  subtype  A  and  luminal  subtype  B  
30,31,32,33.  More  recently,  a  new  subtype  classified  as  “claudin-­low”  has  also  been  
idientified34. Ongoing   molecular   classification   studies   will   ultimately   allow  
stratification  of  patients  for  a  more  personalized  treatment  based  on  molecular  
alterations.   This   will   provide   useful   information   regarding   patient-­specfic  
prognosis   and   risk   of   relapse   probability   for   complete   response,   not   only   in  
breast  cancer,  but  also  in  many  other  cancer  types.   
  
It  is  well  known  that  breast  cancer  is  a  genetic  disease.  Breast  tumorigenesis  is  
best  described  by  a  multi-­step  progression  model4,   in  which  the  normal  breast  
epithelium   evolves   via   hyperplasia   and   carcinoma   in   situ   into   an   invasive  
cancer,  which   eventually   can   disseminate   via   lymph   and   vascular   systems   to  
form  metastases.  Each  of  these  steps  may  be  the  result  of  one  or  more  distinct  
mutations  in  regulatory  genes.  Several  somatic  mutations  in  these  genes  have  
been   found   in  breast   cancer  cells.   Mutational   activation   of   oncogenes,   often  
coupled   with   non-­mutational   inactivation   of   tumour   suppressor   genes,   is  
probably  an  early  event   in  sporadic   tumours,   followed  by  mutations   in  multiple  
additional   genes,   leading   to   tumorous   cancer   development.   Oncogenes   that  
have  been   reported   to   play  an  early   role   in   sporadic   breast   cancer   are  MYC,  
CCND1  (Cyclin  D1)  and  ERBB2  (HER2/neu).  Sporadic  breast  cancer  accounts  
for  70-­80%  of   the  cases.  Less  commonly,  germline  mutations  predispose   that  
individual   to   develop   breast   cancer.   However,   the   inheritance   of   a   mutated  
cancer   susceptibility   allele   of   a   high   penetrance   susceptibility   gene   (such   as  
BRCA1,   BRCA2,   TP53   or   PTEN)   is   only   the   first   step   in   promoting   the  
development  of  a  malignancy  and  does  not  guarantee  that  an  individual  will  go  
on  to  develop  a  particular  malignancy35.  The  development  of  a  heritable  cancer,  
as  well  as  most  other  cancers,  is  postulated  to  be  dependent  on  the  occurrence  
of   a   second   genomic   alteration   (Knudson’s   “two-­hit”   model)36.   The   current  
consensus   is   that   these   are   'caretaker'   genes,  which,  when   inactivated,   allow  
other  genetic  defects  to  accumulate37.  Moreover,  analysis  of  molecular  features  
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of  early  stage  breast  cancer  using  NGS  has  confirmed  that  TP53  and  PIK3CA  
mutations   are   the   most   frequent   genomic   alterations   overall   in   all   intrinsic  
subtypes   (28%   for  both  genes)3.  Amplifications   in  ERB2,  FGFR1   and  CCND1  
follow   in   frequency,   being   observed   in   10-­20%  of   all   breast   cancer   subtypes.  
PTEN   mutations   and   deletions,   among   many   others   genes,   including  KRAS,  
APC,  NF1,  SKT11,  MAPK2K4,  MAP3K1  and  AKT2  can  also  be  altered  in  breast  
cancer2.  Environmental  and  lifestyle  factors  also  influence  whether  a  person  will  
develop  breast  cancer38.  Recognized  risk  factors  for  breast  cancer  development  
include   hormonal,   reproductive,   and   menstrual   history,   age,   lack   of   exercise,  
alcohol,  radiation,  benign  breast  disease,  and  obesity39.  
  
1.2.  DNA  Methylation  in  Cancer  
  
Decades  of  research  have  led  to  a  substantial  understanding  of  the  factors  that  
cause   or   are   associated   with   development   of   breast   cancer   and   lead   to   the  
appearance  of  a  neoplasm,  characterized  by  a  variety  of  genetic   lesions,  such  
as  gene  amplifications,  gene  deletions,  point  mutations,  loss  of  heterozygosity,  
chromosomal  rearrangements,  and  overall  aneuploidy.  Even  though  the  genetic  
origin  of  cancer   is  widely  accepted,  epigenetic  alterations  are  among  the  most  
common   molecular   alterations   in   human   neoplasia40.   These   include   DNA  
methylation,   histone   modifications,   nucleosome   positioning   and   aberrant  
expression   of   non-­coding   RNAs,   specifically   microRNAs41.   Both   genetic   and  
epigenetic   alterations   interact   at   all   stages  of   cancer  development   to  promote  
cancer   progression42,43,44,45.   For   instance,   EZH2,   the   writer   of   the   histone   H3  
lysine  27  trimethylation  (H3K27me3)  mark  associated  with  Polycomb  repressive  
complex   2   (PRC2),   is   overexpressed   in   aggressive   breast   cancer   as   a  
consequence   of   genetic   upstream   mutations   in   BRCA1.   As   a   consequence,  
EZH2   leads  to  cancer  cell  migration  and  invasion  by  methylating  and  silencing  
important  differentiation  genes46.  
  
Altered  DNA  methylation  patterns  is  the  most  studied  epigenetic  modification  in  
cancer,   which   has   been   considered   as   a   hallmark   of   the   disease47,48,49.   DNA  
methylation   refers   to   the   addition   of   a   methyl   group   covalently   to   the   base  
cytosine.  In  vertebrates,  DNA  methylation  mainly  occurs  at  cytosines  in  a  CpG  
dinucleotide   context50.   Most   CpG   dinucleotides   in   the   human   genome   are  
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methylated.   However,   CpGs   are   not   normally   distributed,   as   they   have   been  
severely   depleted   in   the   vertebrate   genome   to   about   20%   of   the   predicted  
frequency. The only exception for this global CpG depletion resides in a specific 
category of GC- and CpG-rich sequences termed CpG islands that are  found  at  
increased   density   in   the   promoters   of   genes51,   where   they   are generally 
unmethylated52.  
 
This  modification  is  involved  in  regulating  many  processes,  including  embryonic  
development,  transcription,  genomic  imprinting,  among  others18.  Consistent  with  
these   important   roles,   DNA   methylation   is   associated   with   transcripcional  
silencing   and   aberrant   methylation   may   play   a   role   in   silencing   of   tumour  
suppressor  genes.  For  gene  transcription  to  occur,  the  gene  promoter  should  be  
accessible   to   transcription   factors   (TFs)   and   other   regulatory   units53.   DNA  
methylation  can  directly  prevent  transcription  factor  binding  and  lead  to  changes  
in   chromatin   structure   that   restrict   access   of   TFs   to   the   gene   promoter54.  
Interestingly,   some   developmentally   important   human   TFs   prefer   to   bind   to  
methylated  CpG  sites,  thus  methylation  exerts  a  selecive  effect  on  factors  that  
binds   to  a   target  sequence55.   In  many  human  diseases,   including  cancer,   it   is  
acknowledged  that  aberrant  methylation  or  hypermethylation  of  promoters  alters  
the  expression  of  a  variety  of  critical  genes,  such  as  tumour  suppressor  genes,  
affecting   different   transcriptional   pathways   and   hence   facilitating   the  
development  of  malignant  tumours41.    
Overall,   DNA   methylation   alterations   play   an   important   role   in   all   stages   of  
multistep  tumorigenesis  from  the  early  onset  of  malignant  transformation56,57,58.  
With   the   advent   of   NGS   technologies   we   have   obtained   genome-­wide   DNA  
methylation   maps   at   high   resolution   that   reveal   new   key   players   in   cancer,  
including   breast   cancer.   Initial   clinical   data   strongly   suggests   that   DNA  
methylation  signatures  may  be  useful   tumour  biomarkers   for  cancer  detection,  
diagnosis   and   prognosis59,   and   especially   in   early   detection   of   the   disease.  
Moreover,  unlike  genetic  alterations,  DNA  methylation  is  reversible,  rendering  it  
a   potential   target   for   novel   therapy   approaches60.   For   this   reason,   epigenetic  
alterations   are   leading   candidates   for   the   development   of   specific   markers.  
Although  epigenetic  alterations  are  well  characterised  to  be   involved   in  cancer  
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development,   current   diagnostic   techniques   are  well   behind   current   biological  
knowledge.  
1.3.  Breast  Cancer  Screening  Methods    
Mammography  is  the  most  widely  used  screening  method,  with  solid  evidence  of  
benefit   for   women   aged   40   to   74   years.   Clinical  breast  examination   and   breast  
self-­exam  have   also   been   evaluated   but   are   of   uncertain   benefit61.  Overall,   the  
breast   screening   program   finds   cancer   in   about   8   out   of   every   1.000   women  
having  screening62.  This  benefit   is  greater   for  women  who  are  at  higher   risk   for  
breast  cancer  based  on  older  age  or  other  risk  factors  such  as  family  history.    
Despite   mammography   screening   may   be   effective   in   reducing  breast  
cancer  mortality   in   certain   populations,   it   can   pose   harm   to   women   who  
participate.   The   limitations   are   best   described   as   false   positives   (related   to   the  
specificity  of  the  test),  overdiagnosis  (true  positives  that  will  not  become  clinically  
significant),   false   negatives   (related   to   the   sensitivity   of   the   test),   discomfort  
associated   with   the   test,   radiation   risk,   and  anxiety63.   About   half   or   more   of  
women  who   have   a  mammogramy   early   for   10   years  will   have   a   false-­positive  
mammogram,   and   up   to   20%   of   these   women   will   need   a   biopsy.   For   some  
women   undergoing   regular   screening,   the   mammogram   may   find   an   invasive  
cancer   or   noninvasive   condition   (ie,   ductal   carcinoma   in   situ)   that   would   never  
have   caused   problems.   There   is   about   a   19%   chance   that   the   cancer   is   being  
overdiagnosed,  and  patients  will   receive  unnecessary  treatment.  Moreover,  13%  
of  breast  cancers  are  undetectable  by  mammography  due  to  tumour  size  and  age  
of  patients,  thus  being  more  advanced  when  diagnosed,  as  they  may  grow  longer  
before  being  detected  by  a  screening  mammogram63.  In  addition,  currently  used  
biomarkers   with   low   accuracy,   such   as   cancer   antigen   CA15-­3   and  
carcinoembryonic  antigen  (CEA),  have  been  recommended  against  for  accurately  
diagnosing  breast  cancer64.  
For  decades,  there  has  been  strong  interest   in  screening  strategies  that  would  
be  able  to  detect  early  cancers  before  they  progress,  thereby  reducing  mortality.  
Even   though   mammography   screening   appears   to   reduce   breast   cancer  
mortality,   for   some  patients,   the  harms  may  outweigh   the  benefits.  Therefore,  
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better   breast   cancer   screening   tests   are   needed.   Nevertheless,   early   breast  
cancer  detection  is  dependent  on  sensitive  and  specific  screening  methods65.  
  
1.4.  Genotyping  Tumour  Tissue  vs  liquid  biopsies  
  
Imaging   studies   such   as   mammogram   and   MRI,   often   along   with   physical  
exams   of   the   breast,   can   lead   doctors   to   suspect   that   a   person   has   breast  
cancer.  However,  the  only  way  to  confirm  the  existence  of  a  tumour  is  to  take  a  
sample   of   the   tissue   from   the   suspicious   area   and   examine   it   under   a  
microscope66.   Tissue   biopsy   is   also   the   gold   standard   for   clinical   and  
investigational  sequencing,  but  barriers  exist   in   terms  of  acquisition  and  utility.  
Likely,  the  major  limitation  of  tissue  biopsy  is  heterogeneity,  which  characterizes  
most  advanced  cancers67,68.  Cancers  are  heterogeneous,  with  different  areas  of  
the   same   tumour   showing   different   genetic   profiles   (ie,   intratumoral  
heterogeneity);;   likewise,   heterogeneity   exists   between   metastases   within   the  
same  patient  (ie,  intermetastatic  heterogeneity).  A  biopsy  or  tissue  section  from  
one   part   of   a   tumour   will   miss   the   molecular   intratumoral   as   well   as  
intermetastatic  heterogeneity69.  Moreover,  biopsies  are  expensive  and  invasive  
procedures  for  patients  that  can  lead  to  clinical  complications.  To  overcome  the  
limitations   of   tissue   biopsies,   less   invasive,   cost-­effective   and   highly   sensitive  
and   specific   techniques   capable   of   capturing   tumour   heterogeneity   and   the  
molecular   changes   that   cancer   cells   undergo   are   needed   to   detect   and  
diagnose  breast  cancer64.    
  
When   a   comprehensive   analysis   of   the   overall   disease   is   required   or   when  
tissue  specimens  are  difficult  to  obtain  or  are  unavailable,  liquid  biopsies  are  an  
attractive  alternative  option.  This  is  because  circulating  tumour  DNA  fragments  
contain   identical   genetic   defects   to   those   in   the   tumours   themselves   and  
cancer-­related  molecular  alterations  can  be  detected   in  cfDNA.  These   include  
somatic   point   mutations,   loss   of   heterozygosity   (LOH),   translocations,   gene  
copy  number  changes  and  DNA  methylation  changes70.  Thus,  cfDNA  tests  may  
potentially   overcome   problems   related   to   tumour   heterogeneity   and  
accessibility71.  Also,   repeated  blood  samples  can  be   taken   in  order   to  monitor  
changes   in   cfDNA   in   the   natural   course   of   the   disease   or   during   cancer  
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treatment72.  In  the  detection  of  metastatic  breast  cancer,  cfDNA  shows  superior  
sensitivity   to   that   of   other   conventional   tumour   biomarkers   and   has   a   greater  
dynamic   range   that   correlates  with   changes   in   tumour  burden73.  Furthermore,  
the   accuracy   of   advanced   qualitative   analysis   showed   even   higher   level   of  
discriminatory  power  in  breast  cancer  detection64.    
1.5.  cfDNA  as  a  potential  novel  screening  method  
  
In  1948,  Mandel  and  Metaís  discovered  for  the  first  time  the  presence  of  DNA  in  
human  blood74,  termed  as  circulating  cell-­free  DNA  (cfDNA).  All  cells,  including  
tumour   cells   and   non-­malignant   cells,   shed  DNA,   called   cfDNA,   into   the  
circulatory  system.  Circulating  tumour  DNA  (ctDNA)  is  cfDNA  that  is  shed  from  
tumour   cells   into   the   circulatory   system.   These   molecules   can   be   easily  
sampled  from  circulating  blood,  an  approach  known  as  liquid  biopsy.  In  healthy  
individuals,   plasma   cfDNA   is   believed   to   derive   primarily   from   apoptosis   of  
normal  cells  of  the  hematopoietic  lineage,  with  minimal  contributions  from  other  
tissues75.   Furthermore,   the   levels   of   cfDNA  have  been   shown   to   be   higher   in  
cancer   individuals   than   in   healthy   individuals,   and   correlates   with   tumour  
metastasis,   response   to   therapy  and   recurrence76.  As   the   tumour   increases   in  
volume,   so   too  does   the   cellular   turnover   and  hence   the  number   of   apoptotic  
and  necrotic   cells67,68.  Under   normal   physiologic   circumstances,   apoptotic   and  
necrotic   remains  are   cleared  by   infiltrating  phagocytes.  This  does  not   happen  
efficiently  within  the  tumoral  mass,  leading  to  the  accumulation  of  cellular  debris  
and  its  inevitable  release  into  the  circulation69.  
In   addition   to   quantitative   changes,   qualitative  alterations  of   circulating   cfDNA  
have   also   been   observed,   such   as   microsatellite   alterations77,   oncogenes,  
tumour   suppressor,   and   other   somatic   gene   mutations78,   mitochondrial   DNA,  
viral  DNA79  and  tumour-­specific  methylated  DNA.    
  




Figure   2:  Mutations,  methylation,   DNA   integrity,  microsatellite   alterations   and   viral  
DNA  can  be  detected   in  cfDNA   in  blood.  Reproduced  from  Schwarzenbach,  Hoon  and  
Pantel,  Nat  Rev  Cancer,  426–437  (2011).     The  release  of  DNA  from  tumour  cells  can  be  
through   various   cell   physiological   events   such  as   apoptosis,   necrosis   and   secretion.   The  
physiology  and  rate  of   release   is  still  not  well  understood;;   tumour  burden  and  tumour  cell  
proliferation  rate  may  have  a  substantial  role  in  these  events80.  
  
  
The   release   of   cell-­free   nucleic   acids   (cfNAs)   into   the   bloodstream  occurs   by  
different  sources,  including  the  primary  tumour,  tumour  cells  that  circulate  in  the  
blood,   and   micro-­metastatic   deposits   that   are   present   at   distant   sites,   (for  
example,  bone  marrow  and  liver),  and  normal  cell  types,  such  as  hematopoietic  
and  stromal  cells81.  The  physiological  events  that  lead  to  the  increase  of  cfNAs  
in   the   blood   during   cancer   development   and   progression   comprise   increased  
apoptotic   and   necrotic   cell   deaths   as   well   as   active   secretion   into   the   blood  
circulation82,83.   Necrotic   and   apoptotic   cells   are   usually   phagocytosed   by  
macrophages  or  other  scavenger  cells84.  Macrophages  then  release  fragmented  
cfDNA   into   the   bloodstream.   These   mechanisms   are   passive   cfDNA   release  
mechanisms.   It   is  also  hypothesised   that   cancer   cells   can  secrete  cfDNA   into  
the  bloodstream  actively.  Importantly,  DNA  can  be  shed  as  both  single-­stranded  
and   double-­stranded   DNA   bound   the   nucleosome   or   are   found   inside  
exosomes80.   cfDNA   is   highly   fragmented,   with   most   molecules   being  
approximately  150  bp  in  length.  This  matches  the  length  of  DNA  occupied  by  a  
nucleosome,   the  primary  unit   for  spatial  organization  of  DNA   in   the  nucleus85.  
On  average,  the  size  of  this  DNA  varies  between  small  fragments  of  70  to  200  
base  pairs  and  large  fragments  of  approximately  21  kilobases.  Physiologically,  
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cfDNA   is   removed   from   15   minutes   to   several   hours   from   the   circulation   by  
blood   nuclease   activity   and   filtration   of   kidney   and   liver80.   The   cfDNA   is  
extracted   from   the  plasma  or   serum   fraction  of   the  blood.  However,   there  are  
some   challenges   in   working   with   cfDNA,   such   as   the   low   concentration   of  
cfDNA   in   the   circulation   and   high   admixture   of   normal   DNA   in   cfDNA   pose  
major   challenges   for   the   development   of   sensitive   and   robust   detection  
pipelines84,86.  
  
In  addition  to  cfDNA,  other  circulating  bioamarkers  can  be  analysed  using  liquid  
biopsies,   including   circulating   tumour   cells   (CTCs),   cell-­free   mRNA   (cfRNA),  
microRNAs   (miRNAs),   exosomes,   proteins   and   metabolites.   In   terms   of  
detection,  only  1   to  10  CTCs  per  ml  of  whole  blood  are   found   in  patients  with  
metastasic   disease87,   therefore   the   isolation   and   characterization   of   CTCs  
presents   a   technical   challenge.   In   fact,   current   CTC   technologies   only   can  
detect   60   to   80%   of   patients   with   known   metastases.   In   contrast,   cfDNA  
analysis   is   demonstrably  more   sensitive   than  CEA  measurement   (the   current  
standard  blood  biomarker)  to  define  stage  II  colon  cancer  patients  at  very  high  
risk   of   recurrence   after   resection,   even   after   completion   of   adjuvant  
chemotherapy88.   In  addition,   cfRNA  and  circulating  mRNA  are  also  present   in  
the   blood,   either   in   circulating   ribonucleoprotein   complexes   or   packaged   into  
exosomes.   These   molecules   have   been   detected   in   the   plasma   of   cancer  
patients,  using  microarray  technologies  and  quantitative  real-­time  RT-­PCR,  and  
led   to   the   detection   of   expression   patterns   specific   for   aggressive   prostate  
cancer89.   Furthermore,   exosomes   with   cancer   mRNA   transcripts   as   well   as  
dsDNA   as   a   result   of   active   secretion   by   tumour   cells,   are   promising  
biomarkers90.   Nevertheless,   these   are   difficult   to   isolate   and   are   very   rare   in  
clinical   samples   compared   to   those   coming   from   normal   cells   that   are   much  
more  abundant.    
Taken   together,   further  studies  of   the  biology  of   these  molecules  are   required  
and   standarised   techniques   need   to   be   developed,   but   it   is   clear   that   cfDNA,  
CTCs   and   circulating   RNA   have   the   potential   to   be   translated   into   the   clinic  
when   acceptable   levels   of   sensitivity   and   specificity   are   achieved.   Ultimately,  
combined   assessment   of   different   biomarkers   will   increase   the   sensitivity  
required   for   early   cancer   detection.   For   instance,   Fackler   et   al   have   already  
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developed   cMethDNA,   a   quantitative   multiplexed   methylation-­specific   PCR  
assay   for   a   panel   of   genes,   and   have   detected   and   validated   methylation  
signatures  of  known  breast  cancer  markers  in  tumour  DNA  of  metastasic  breast  
cancer   patients   with   a   sensitivity   and   a   specificity   of   91%   and   96%,  
respectively91.  
  
1.6.  Methodology  in  CpG  Dinucleotide  Methylation  Analysis  
Current  epigenetic  analysis   focus   in   the   investigation  of  DNA  methylation  and  
chromatin  modification  patterns,  and  more  recently,  studies  have  been  directed  
toward   a   genome-­wide   assessment92.   As   DNA   methylation   effectively   down-­
regulates  gene  activity,  methylation  profiling  of  specific  CpG  islands  appears  to  
be   a   promising   approach   for   cancer   risk   assessment   for   its   known   role   in  
tumorigenesis,   but   also   because   it   is   involved   in   many   other   genetic  
disorders49,80.  Of   especial   interest   is   the   study  of   cfDNA  methylation  patterns,  
since  plasma  contains  a  mixture  of  DNA  from  different   tissues  and  organs.  As  
certain   methylation   patterns   are   tissue   specific,   they   could   serve   as   an  
epigenetic   signature   for   the   respective   cells   or   tissues   that   release   their  DNA  
into  the  circulation93.    
There   are   many   techniques   to   analyze   changes   in   CpG   dinucleotide  
methylation,   depending   on   factors   such   as   the   availability   of   the   DNA   or   the  
number  of  targets  to  analyze.  CpG  dinucleotide  methylation  analysis  is  enabled  
through  bisulfite  modification  of  DNA,  which  was  first  investigated  by  Hayatsu  et  
al   (1970)94.   Bisulfite  modification   converts   nonmethylated   cytosines   to   uracils,  
which   are   then   converted   to   thymines   during   DNA   amplification   by   PCR,  
whereas  methylated  cytosines  are  protected  from  bisulfite  modification  95.  After  
the   bisulfite   treatment,   PCR   amplification   with   specific   methylation   primers  
allows   to  determine   the  methylation  status   in   the  CpG  of   interest.  Sequencing  
analysis  of  bisulfite-­converted  DNA   is   regarded  as  a  gold-­standard   technology  
to   qualitative   and   quantitatively   reveals   the   methylation   status   at   single  
nucleotide   resolution96.   In   order   to   reach   this   goal,   PCR   amplification   in   this  
study   was   carried   out   with   Fluidigm   Access   Array.   It   is   a  microfluidics-­based  
technology  that  enabled  amplification  of  48  samples  with  48  primer  pairs  in  one  
run  on  a  single  chip.  The  workflow  consists  of  sample  and  primer  loading,  PCR  
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amplification   and   sample   pooling,   followed   by   sequencing   and   analysis97.  
Fluidigm   enables   amplification   of   2304   (48   x   48)   reactions   per   chip   by  
separating  these  reactions  in  nanoliter  microchambers.  Approximate  amount  of  
starting  DNA  for  Fluidigm  can  be  as  low  as  0.05μg,  which  is  suitable  for  the  low  
concentration  of  cfDNA  that  can  be  extracted  from  plasma98.    
1.7.  Background  data  for  this  research  project  
The   Illumina   EPIC  Methylation   Array   previously   carried   out   in   the   host   group  
interrogated  over  850,000  methylation  sites  quantitatively  across  the  genome  at  
single-­nucleotide   resolution.   The   Infinium  MethylationEPIC  BeadChip   includes  
more   than   90  %   of   the   CpGs   on   the   HumanMethylation450   (HM450)   and   an  
additional   413,743   CpGs   at   regions   identified   as   potential   enhancers.   The  
proportion   of   DNA   methylation   at   a   particular   CpG   site   (also   called   the  
methylation   beta-­value   (β))   is   then   ascertained   by   taking   the   ratio   of   the  
methylated  (C)  to  unmethylated  (T)  signal,  using  the  formula:    
𝛽 =
Intensity	  of	  the	  methylated	  signal
(Intensity	  of	  the	  unmethylated	  signal	   + 	  Intensity	  of	  the	  methylated	  signal)  
A   β   of   0   represents   a   completely   unmethylated   CpG   site   and   a   β-­value  
approaching  1   represents  a   fully  methylated  CpG  site99.  This  platform  allowed  
profiling   of   CpG   dinucleotide   methylation   in   18   paired   samples   consisting   of  
tumour  tissue  and  buffy  coat  recruited  from  patients  with  breast  cancer.  A  total  
of   3172   probes   obtained   median   methylation   differences   of   more   than   40%  
between  tumours  and  the  paired  buffy  coat  in  these  patients  (Fiona  Semple  and  
Gil  Tomas,  IGMM,  Personal  communication).  At  this  stage  of  the  project,  buffy  
coat  is  used  as  a  surrogate  for  plasma  cfDNA  because  most  non-­tumour  cfDNA  
is  anticipated  to  derive  from  leucocytes100,75.    
Probes   having   extreme   beta-­values   in   leucocyte   samples   (i.e.   methylation  
levels   of   less   than   5%  and  more   than   95%)  were   ranked   by   q-­value,  median  
differences   and  widest   beta   value   separation   between   tumour   and   buffy   coat  
samples  (Figure  3).  Unique  probes  intersecting  these  3  criteria  made  up  a  total  
of    168  probes  that  were  used  for  Fluidigm  Access  Array  primer  design.  




Figure  3:  Dot  plots  showing  comparisons  between  tumour  and  buffy  coat  of  patients  
with   breast   cancer   measured   by   EPIC   array.   Probes   were   ranked   by   qval,   median  
difference  and  widest  beta  value  separation  between  tumour  and  buffy  coat  samples  using  
Funnorm  pre-­processing  method.   (Unpublished  data   from  host   group:   Fiona  Semple   and  
















The  working  hypothesis  of   our   group   is   that  methylation  differences  observed  
between   primary   tumours   and   leucocytes   can   be   translated   into   methylation  
patterns  in  cfDNA.  
3.  RESEARCH  PROJECT  AIMS  
This  research  aims  to  establish  methods  to  reliably  detect  methylation  changes  
to  allow  development  of  cancer  biomarkers  for  non-­invasive  early  detection.    
In  order  to  achieve  this,  this  research  aims  to  (1)  detect  methylation  differences  
between   matched   tumour   samples   and   leucocytes   of   patients   with   breast  
cancer,   and   in   cfDNA   using   the   Fluidigm   Access   Array,   and   (2)   test   the  
sensitivity   of   bisulfite   Sanger   sequencing   and   bisulfite   pyrosequencing   as  



































The   methodology   of   this   project   (Figure   4)   consisted   of   DNA   bisulfite  
conversion,  optimization  of  marker  design,  primer  pair  design  and  validation  for  
Fluidigm  and  Sanger  Sequencing  and  Pyrosequencing  as  validation  methods,  
Fluidigm   Acccess   Array   Amplification,   Illumina   MiSeq   sequencing,   read  
alignment   and   methylation   calling,   statistical   analysis   and   correlation   of  
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4.1.  Research  samples  
Research  samples  for  this  study  were  provided  by  Olga  Oikonomidou,  clinician  
scientist  at  the  Edinburgh  Cancer  Research  Center.    DNA  samples  consisted  of  
extracted   DNA   samples   of   breast   tumour   tissue   and   leucocytes   from   10  
different   breast   cancer   patients   before   receiving   neoadjuvant   treatment.  
Patients  ranged  ages  36  to  69  years  old  and  they  were  all  classified  as  ductal  
carcinoma   of   no   special   type   (NST)   of   breast   cancer.   In   addition,   4   cfDNA  
samples  from  different  healthy  individuals  were  used  in  this  experiment.  Plasma  
was  separated  in  SeraLabs  laboratory  by  centrifugation  within  30  minutes  after  
blood  draw.  This  prevented  from  lysis  of  leucocytes  which  would  result  in  a  non-­
cfDNA  contribution   to   the  plasma.  After   that,  cfDNA  samples  were  sent   to   the  
University   of   Edinburgh   and   cfDNA   extraction   was   carried   out   by   Dr.   Fiona  
Semple  from  Institute  of  Genomics  and  Molecular  Medicine  (IGMM),  University  
of  Edinburgh  (UoE).  All   the  samples  used  had  been  previously   isolated  by  Dr.  
Fiona  Semple.    
  
4.2.  Fluidigm  Access  Array  Amplification  
4.2.1.  Marker  Design  and  Optimization  for  Fluidigm  Access  Array  
The  original  raw  data  from  the  Illumina  EPIC  methylation  array  was  re-­analysed  
with   the   package   minfi101   using   an   alternative   pipeline   (Fig.   3).   The  
normalization  of  the  data  from  the  Illumina  EPIC  array  was  optimized  using  the  
Funnorm  pre-­processing  method102,  which  is  recommended  for  datasets  where  
global  biological  methylation  differences  exist  between  samples,  such  as  cancer  
and  normal  tissues.    
In   addition,  minfi   provides  a  quality   control   based  on   the   log  median   intensity  
coming   from   CpGs   in   the   EPIC   array,   where   good   samples   may   cluster  
together,   while   failed   samples   tend   to   separate   and   have   lower   median  
intensities101.   After   that,   questionable   probes   such   as   those   containing  
polymorphisms  and  those  with  potential  to  cross-­hybridise  were  also  removed.  
Probes   having   extreme   beta-­values   in   leucocyte   samples   (i.e.   methylation  
levels   of   less   than   5%  and  more   than   95%)  were   ranked   by   q-­value,  median  
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differences   and  widest   beta   value   separation   between   tumour   and   buffy   coat  
samples  (Figure  5).  Q-­value  provided  statistical  robustness  for  the  assessment  
of  methylation   differences   between   tumour   and   healthy   samples   by   the  EPIC  
array;;   median   differences   accounted   for   the   variability   on   CpG   methylation  
among      the   different   samples;;   the   widest   beta   value   provided   the   maximum  
difference   in  methylation   between   cancer   and   healthy   samples.  Hence,   these  
criteria  aimed  to  identify  the  probes  that  could  be  used  for  reliably  distinguishing  
methylated   cytosines   in   tumour   DNA   in   a   background   of   non-­methylated  
cytosines   from   the   non-­tumour  DNA   in   a   tumour   sample   or   vice   versa.   Thus,  
unique  probes  intersecting  these  three  criteria  made  up  a  total  of  168  probes  for  
primer  design  and  validation.  
  
Figure   5:   Pipeline   for   optimal   marker   design   for   CpG   dinucleotide   methylation  
detection.    
4.2.2.  PCR  Primer  Design  and  Validation  
Human  Genome   data  was   obtained   from  University   of   California,   Santa  Cruz  
(UCSC)   genome   database.   Human   genome   from   December   2013   assembly  
(GRCh38/hg38)  was  used  as  donor  sequence  for  primer  design.  Strand  specific  
primers  were  designed  across  the  CpGs  of  interest  by  using  PrimerSuite  primer  
design  tool103.      
Tissue-­‐specific	  methylation	  signatures	  
Methylation	  markers	  only	  found	  in	  breast	  tissue	  
Top	  probes	  intersecting
q-­‐value Median	  difference 𝛽-­‐value	  distance	  between	  tumour	  and	  leucocytes
Thresholds	  in	  methylation	  levels
Methylation	  of <5%	  in	  leucocytes	  and	  >20%	  in	  
tumour	  samples
Methylation	  of	  >95%	  in	  leucocytes	  and	  <80%	  in	  
tumour	  samples
Non-­‐specific	  probes	  with	  potential	  to	  cross	  hybridise
Polymorphic	  probes	  (SNPs	  >	  0.05)
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Primers   were   designed   to   be   between   20bp   and   30bp,   with   a   melting  
temperature   (Tm)   between   60ºC   and   64ºC   and   to   avoid   CpGs   in   the   primer  
sequences.    As  cfDNA  is  overall  consistently  shorter  than  the  fragment  length  of  
normal  cell-­free  DNA104,  the  amplicon  size  ranged  between  125bp  and  140  bp.  
They   were   tested   by   in   silico   PCR   against   the   bisulfite   converted   human  
genome   (UCSC   hg38).   The   pipeline   allows   selection   of   primer   pairs   that  
produce   one   specific   amplicon   and   removal   of   products   larger   than   135bp.  
Designed  primer  pairs   (Appendix  1)  were  added  with  common  sequence   tags  
for   Fluidigm   analysis.   The   common   sequence   tag   for   forward   and   reverse  
primer   were   5’-­   ACACTGACGACATGGTTCTACA-­3’   and                                                                                                  
5’-­  TACGGTAGCAGAGACTTGGTCT-­3’,  respectively.    
Primer   pairs   were   validated   by   PCR   amplification   with   bisulfite   converted    
human  genomic  DNA  to  ensure  primers  could  successfully  amplify  the  regions  
of  interest.  The  PCR  reaction  consisted  of  1μl  of  primer  solutions  (1μM  CS1-­  TS  
Forward   Primer   and   1μM  CS2-­TS   Reverse   Primer)   and   4μl   primer   validation  
mixture   (1x   FastStart   High   Fidelity   Reaction   Buffer   without   MgCl2,   4.5mM  
MgCl2,  5%  DMSO,  200μM  PCR  Grade  Nucleotide  Mix,  0.05U/μL  FastStart  High  
Fidelity   Enzyme   Blend,   1x   Access   Array   Loading   Reagent,   8.3ng/μl   bisulfite  
converted   genomic   DNA   and   PCR   grade   dH2O).   PCR   cycles   consisted   of   a  
cycle  of  70ºC  20  minutes,  a  cycle  of  pre-­denaturation  at  95ºC  for  10  minutes,  40  
cycles  of  denaturation,  annealing  and  extension  at  95ºC  for  15  seconds,  57ºC  
for   30   seconds   and   72ºC   for   60   seconds,   respectively,   and   a   final   extension  
cycle  at  72ºC  for  2  minutes.  PCR  products  were  run  on  1,5%  (w/v)  agarose  gel  
electrophoresis  with   10μl  SybrSafe  per   100ml   of   gel.  DNA   ladder   used   in   the  
experiment   was   100bp   quickload   DNA   ladder   (NEB).   Gels   were   visualised  
under  UV  light  in  gel  documentation  system.    
4.2.3.  Preparation  of  Fully  Methylated  and  Unmethylated  DNA  controls  
Fully  methylated  human  genomic  DNA  was  commercially  available  (Roche).  Fully  
unmethylated  DNA  was  prepared  using  the  REPLI-­g  whole-­genome  amplification  
kit  (Qiagen)  following  the  manufacturer’s  instructions.  
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4.2.4.  Bisulfite  Conversion  of  DNA  
DNA   bisulfite   conversion   was   carried   out   to   enable   quantification   of   CpG  
dinucleotide  methylation.   The   bisulfite   conversion   comprises  DNA   denaturation,  
bisulfite   deamination,   desulfonation   and   several   washing   steps.   DNA   of   each  
sample  was  bisulfite-­converted  using  MethylCodeTM  Bisulfite  Conversion  kit  (Life  
Technologies)   according   to   the   manufacturer’s   instruction   with   modifications.  
Modifications  involved  the  use  of  a  total  of  250ng  diluted  in  20  μl  water  for  paired  
tumour   and   leucocyte   samples,   and   20   μl      of   cfDNA   sample   as   input   for   DNA  
bisulfite   conversion.  Centrifugation  steps  were  carried  out  at  12000g,  and  a  dry  
centrifugation  step  at  15000g  was  carried  out  before  elution  with  new  collection  
tube.    
4.2.5.  Fluidigm  Access  Array  Amplification  
Fluidigm  Access  Array,   a  48.48  microfluidics   technology,  was  used   to  amplify  
samples  of  bisulfite  converted  DNA  with  validated  primer  pairs.  Primer  solutions  
20x  were  prepared  from  50μM  CS1-­TS  forward  primer,  50μM  CS2-­TS  reverse  
primer,  20x  access  array  loading  reagent  and  TE  buffer  with  final  concentration  
of  1μM  for  each  primer,  1x  access  array  loading  reagent  and  a  total  volume  of  
100μl.   Primer   solutions   20x   were   mixed   with   vortex   for   30   seconds   and  
centrifuged  briefly  to  spin  down  all  components.    
Fluidigm   master   mix   contained   1x   FastStart   High   Fidelity   Reaction   Buffer  
without  MgCl2,  4.5mM  MgCl2,  5%  DMSO,  200μM  PCR  Grade  Nucleotide  Mix,  
0.05U/μL   FastStart   High   Fidelity   Enzyme   Blend,   1x   Access   Array   Loading  
Reagent  and  dH2O.  A  total  volume  of  3.5μl  was  aliquoted  into  96-­well  plate  for  
each  DNA  wells.  Bisulfite  converted  DNA  samples  were  added  into  master  mix  
in  each  well  of  96-­well  plate.  Two  technical  replicates  were  used  in  8  out  of  10  
paired   tumour   and   leucocyte   samples.   Technical   replicates   involved   same  
bisulfite-­converted  DNA  sample  analyzed   twice  by  using   two  different  wells   in  
the  Fluidigm  plate.  CfDNA  samples  were  not  replicated.  







Figure  6:  Primer  plate  designs  of  the  samples  and  primer  pairs  (1B)  used  in  Fluidigm  
Access   Array   amplification.   “B”   and   “T”   samples   correspond   to   buffy   coat   and   tumour  
matched   samples   from   breast   cancer   patients,   respectively;;   FM   and   FUM   are   the   fully  
methylated   and   fully   unmethylated   DNA   controls,   respectively,   and   “cf”   corresponds   to  
cfDNA  from  plasma  of  healthy  individuals.    
A  48.48  access  array  integrated  fluidic  circuit  (IFC)  was  injected  with  control  line  
fluid  and  added  with  500μl  harvest   solution   in  well  H1-­H4.   IFC  was  primed   in  
pre-­PCR  IFC  controller  AX  with  Prime  (151x)  program.    
  
Access  array  harvest  reagents  in  H1-­H4  wells  of  IFC  were  replaced  with  600μL  
of   fresh   reagent.  Each   sample   inlets  were   added  with   1μl   of   1x   access   array  
harvest   reagent.   Samples   were   harvested   by   putting   IFC   in   post-­PCR   IFC  
controller  AX  with  Harvest  (151x)  program.  Samples  were  transferred  into  a  96-­
well  plate.  
  
Figure   7:   Sample   and   primer   inlets  
in  the  Fluidigm  Access  Array  48.48.    
Primed  IFC  was  added  with  4μl  of  sample  mix  
in   left   inlets   and   primer   mix   in   right   inlets  
(Figure   7).   Samples   and   primer   pairs   were  
mixed   by   using   pre-­PCR   IFC   controller   AX  
with  Load  Mix  (151x)  program.  Mixed  samples  
and   primer   pairs   were   put   in   thermocycler.  
PCR  cycles  consisted  of  a  cycle  of  70oC  for  20  
minutes,   pre-­denaturation   at   95oC   for   10  
minutes,   and   40   cycles   of   denaturation,    
annealing   and   extension   at   95oC   for   15  
seconds,  57oC  for  30  seconds  and  72oC  for  60  
seconds  respectively. 
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4.1.7.  Barcoding  and  AMPure  Clean-­up    
Bisulfite-­converted  DNA   samples  were   barcoded.   Barcoding   PCR  master  mix  
contained   1x   FastStart   High   Fidelity   reaction   buffer   without   MgCl2,   4.5mM  
MgCl2,  5%  (v/v)  DMSO,  200mM  of  each  nucleotide  from  PCR  grade  nucleotide  
mix,  0.05U/μl  FastStart  High  Fidelity  enzyme  blend  and  water  to  a  total  reaction  
volume  of  14μl.  A  mixture  of  14μl  mastermix,  4μl  of  barcode  and  2μl  of  bisulfite-­
converted   DNA   samples   was   prepared   in   each   well   for   each   sample.   The  
mixture  was  spun  down  and  put   in   thermocycler.  PCR  program  consisted  of  a  
cycle   of   pre-­denaturation   at   95ºC   for   10   minutes,   15   cycles   of   denaturation,  
annealing,   and   extension   at   95ºC   for   15   seconds,   60ºC   for   30   seconds,   and  
72ºC   for  60  seconds   respectively,  and  a  cycle  of   final  extension  at  72ºC   for  3  
minutes.    
Barcoded  samples  were  pooled  into  a  tube  by  transferring  4μl  for  each  sample.  
Pooled   barcoded   sample  was   purified  with   AMPure   SPRI  magnetic   beads.   A  
total  volume  of  12μl  of  pooled  sample  was  added  with  24μL  of  water  and  43.5μl  
of  AMPure  beads.  Mixture  was  incubated  at  room  temperature  for  15  minutes,  
applied  to  magnetic  field  for  15  minutes  and  70μl  of  the  liquid  was  removed  from  
the   tube.  DNA  bound   to  magnetic  beads  was  washed  with  200μl  of  80%  (v/v)  
ethanol  twice,  air-­dried  and  re-­suspended  in  40μl  of  water.  Samples  were  mixed  
with  vortex  briefly,  incubated  at  room  temperature  for  5  minutes,  and  applied  to  
magnetic  field  for  5  minutes.  Finally,  35μl  of  purified  pooled  barcoded  DNA  was  
collected.    
The   pre   and   post   cleaned-­up   barcoded   libraries,   ready   for   sequencing,   and  
random  samples  pre  and  post-­barcode  diluted  by  adding  40  and  10  µl  water,  
respectively,  were  analyzed  with  Agilent  Bioanalyser  DNA  HS  chip  to  determine  
Fluidigm  product  size  at  the  Wellcome  Trust  Clinical  Research  Facility,  UoE.    
Qubit  HS  DNA  quantification  was  carried  out  at  pre-­  and  post-­barcode  random  
individual   samples   and   DNA   library   pools   to   verify   the   presence   of   Fluidigm  
product.  
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4.1.8.  Illumina  MiSeq  Sequencing,  Read  Alignment  and  Methylation  Calling    
Fluidigm   libraries   were   sequenced   with   paired-­end   Illumina   MiSeq   Next  
Generation   Sequencing   (David   Ross   at   Edinburgh   Clinical   Genetics).   Read  
alignment,   methylation   calling   and   analysis   of   bisulfite   sequencing   data   were  
carried  out  according  to  the  analysis  pipeline  of  Dr.  Duncan  Sproul,  University  of  
Edinburgh  (unpublished).    
Figure   8:   Pipeline   used   to   analyse   Fluidigm-­MiSeq   sequencing   data.   FastQ   files  
derived  from  bisulfite  converted  targeted  Illumina  MiSeq  sequencing  were  the  input  files  to  
obtain  coverage  and  methylation  percentage  for  each  CpG  of  interest.      
  
Human      genome   December   2013   assembly105   (GRCh38/hg38)   was  
downloaded   from   University   of   California   Santa   Cruz   (UCSC)   genome  
database106.   Genome   was   bisulfite   converted   and   prepared   with   bismark  
v0.14.3   and   bowtie2   according   to   bismark   user   guide   manual   with   default  
options.  FastQC  software  provided  assessment  of  the  quality  of  the  sequenced  
bases  and  Phred  scores  were  used  to  exclude  low  quality  reads.  Then,  adapter  
trimming   and   alignment   against   the   reference   genome   were   performed.  
Alignment   of   sequencing   results   to   bisulfite   converted   genome   was   also  
performed  with  bismark  v0.14.3  with  default  options   to  obtain  SAM   files.  SAM  
files   of   each   target   amplicon   were   processed   (python   script)   and   BEDtools  
v2.23.0   with   bedtools   coverage   command   and   default   options   to   obtain  
coverage   of   each   amplicon.   SAM   files   were   also   processed   with   bismark  
methylation   extractor   command   from   bismark   v.0.14.3   according   to   the   user  
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guide   with   default   options.   Output   of   bismark   methylation   extractor   was  
processed   (perl   script)   to   separate   total   methylated   and   unmethylated  
amplicons   from   the   files.  Output   of   perl   script   was   BED   files.   BED   files  were  
processed   with   BEDtools   v.2.23.0   coverage   command   to   obtain   total  
methylated   and   unmethylated   per   target   amplicons.   Bismark   methylation  
extractor  command  was  used  to  obtain  individual  CpG  methylation  percentages.  
Data  analysis  was  performed  in  UNIX  programming  language.  Python  and  Perl  
scripts   used   above   were   provided   by   Dr.   Duncan   Sproul   and   automation   of  
commands  was  assisted  by  Dr.  David  Parry   (IGMM,  University  of  Edinburgh).  
Methylation  percentage  was  calculated  with  formula:    
𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛	  % =
𝑇𝑜𝑡𝑎𝑙	  𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑	  𝑎𝑚𝑝𝑙𝑖𝑐𝑜𝑛𝑠
(𝑇𝑜𝑡𝑎𝑙	  𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑	  𝑎𝑚𝑝𝑙𝑖𝑐𝑜𝑛𝑠 + 𝑡𝑜𝑡𝑎𝑙	  𝑢𝑛𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑	  𝑎𝑚𝑝𝑙𝑖𝑐𝑜𝑛𝑠)
×100	    
4.1.9.  Data  Analysis  
Bisulfite  sequencing  data  was  then  analyzed  based  on  successful  amplification  
of   the   samples   and   complete   bisulfite   conversion.   Successful   amplification   of  
the  FMD,  FUM  and  water  controls  were  analyzed  to  ensure  little  contamination  
in  water  used  in  the  experiment  and  an  indicator  of  successful  sequencing.  After  
that,   samples   and  amplicons  were   filtered  based  on   the  number   of   reads  per  
amplicon   to   ensure   amplification   during   the   Fluidigm   experiment.   In   addition,  
CpGs  were   filtered   based   on   successful   bisulfite   conversion   in   both   the   FUD  
and  FMD  positive  controls.  
Moreover,  this  methylation  study  aimed  to  detect  differentially  methylated  CpGs  
between  tumour  and  leucocyte  samples  and  in  cfDNA.  Methylation  levels  for  the  
CpGs   of   interest   are   unknown   and   may   be   different   between   the   different  
tissues  studied.  Moreover,  the  variation  present  in  the  Fluidigm  platform  poses  
the  challenge  of  determining  whether  the  differences  in  methylation  are  caused  
by  biological  differences  or  by  statistical  chance.  The  best  way  to  address  this  
challenge   is   to   use   technical   replicates   of   the   different   samples.   Thus,   two  
technical   replicates   were   used   for   8   out   of   10   paired   tumour   and   leucocyte  
samples   included   in   the   experiment.   Pearson   tests   were   performed   for  
correlation  analysis  by  using  R  studio.  Technical   replicates  allowed  averaging  
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methylation   data   from   CpGs   and   thus   increased   the   power   to   detect  
differentially  methylated  CpGs.  
  
4.1.10.  Statistical  Analysis  of  CpG  Dinucleotide  Methylation  
Statistical   analysis   was   performed   using   R   studio.   Normality   distribution   of  
leucocyte,   tumour   and   cfDNA   data  was   analyzed  with   Saphiro  Wilk   normality  
test   with   95%   confidence   interval.   Paired   test   was   only   performed   to   CpG  
dinucleotide  methylation  data  that  passed  all   the  filtering  criteria.  Comparisons  
were  carried  out   to  samples  with  positive  strong  correlation  between   technical  
replicates.   P-­values   were   adjusted   by   using   the   “BH”   method   (Benjamini,  
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4.3.  VALIDATION  METHODS    
Specific  and  sensitive  analytical  procedures  must  be  developed  and  optimized  
to  target  circulating  molecules  to  show  methylation  differences  between  patients  
and  healthy  subjects.  Most  of  these  recent  efforts  rely  on  the  methylation  level  
of   individual   CpG   sites,   and   they   are   fundamentally   limited   by   the   technical  
noise   and   sensitivity   in   measuring   single-­CpG   methylation86.   In   order   to  
establish   a   validation   method   for   CpG   dinucleotide   methylation   detection   in  
tumour-­cfDNA,  Sanger  sequencing  and  Pyrosequencing  were  performed  to  test  
their   sensitivity   and   reproducibility   for   detecting   small  methylation   differences.  
Probes   that   showed   clear   methylation   differences   between   tumour   and  
leucocytes   were   selected,   and   primer   pairs   were   designed   independently   for  
each   assay   to   test   whether   these   methods   are   able   to   produce   results  
comparable   to   those   produced   by   the   EPIC   methylation   array   and   Fluidigm  
Access  Array.    
Detailed   information   regarding   the   principle   of   Sanger   sequencing   and  
Pyrosequencing  is  given  in  Appendix  1. 
 
4.3.1.   Preparation   of   Fully   Methylated   and   Fully   Unmethylated   Genomic  
DNA  Mixtures  and  Quantification    
Fully  methylated  human  genomic  DNA  was  commercially  available  (Roche).  Fully  
unmethylated  DNA  was  prepared  using  the  REPLI-­g  whole-­genome  amplification  
kit   (Qiagen)   following   the  manufacturer’s   instructions   (as   described   above)   and  
the  purified  with  simple  DNA  precipitation.  A  total  of  1/25  volume  sodium  acetate  
3M  and  1  volume  of  100%  ethanol  were  added   into   the  DNA.  The  mixture  was  
incubated  overnight  at   -­20oC,  and   then  centrifuged  at  12000rpm  for  20  minutes.  
The   pellet  was  washed  with   70%   (v/v)   ethanol,   centrifuged   at   12000rpm   for   20  
minutes,  air-­dried  and  re-­suspended  in  100μl  of  dH2O.  Purified  fully  unmethylated  
DNA   was   quantified   using   Qubit   dsDNA   broad   range   assay   kit   and   the  
concentration   of   both   fully  methylated   and   unmethylated  DNA  were   adjusted   to  
100ng/μl.   When   purified   fully   unmethylated   DNA   was   too   diluted,   the   vacuum  
system  in  Human  Genetics  Unit  (HGU)  was  used  to  reach  100  ng/μl  .  
Both  methylated  and  unmethylated  DNA  were  mixed  as  shown  in  table  1  to  sum  
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the   volume   up   to   5   μl,   and   the   final   concentration   of   500   ng/μl,   which   is   the  
optimal  for  performing  the  bisulfite  conversion,  was  achieved.  DNA  concentration  
was  measured  with   the  Qubit   ssDNA  broad   range  assay  kit   (Life  Technologies)  
according  to  the  manufacturer’s  instructions.  
  
Table  1:  Percentages  of   fully  methylated   (FM)  and  unmethylated   (UM)  DNA  used   to  
make  the  samples.  The  asterisk  *  indicates  that  these  samples  have  a  replicate.  
  
Sample  name   FM  DNA  (%)   UM  DNA  (%)  
1   0   100  
2*   10   90  
3   25   75  
4*   50   50  
5   75   25  
6*   90   10  
7   100   0  
  
Batch  effect  was  avoided  by  replicating  samples  2,  4  and  6,  from  two  independent  
bisulfite   treatments,   with   separate   PCR   amplification,   as   well   as   Sanger  
sequencing  and  Pyrosequencing  experiments  were  performed  for  each  replicate.  
  
4.3.2.  Primer  design  and  validation  for  Bisulfite  Sanger  sequencing  
9  probes  that  showed  well  defined  differences  (Figure  5)  in  methylation  between  
tumour   and   leucocytes   in   the   EPIC   array   were   randomly   selected   to   be  
analysed  by  Sanger  sequencing.    
  
Figure  10:  Dot  plot  showing  comparisons  between  tumour  and  buffy  coat  of  patients  
with  breast  cancer  measured  by  EPIC  array.  The  9  probes  obtained  median  differences  
in  methylation   of  more   than   40%.  Previous   data   from  host   group   (Fiona  Semple   and  Gil  
Tomas,  IGMM,  Personal  communication).  
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Primers  were  designed  as  described  above  except  amplicon  size  150  bp  and  
250   bp   across   the  CpGs   of   interest   by   using   Bisulfite   Primer   Seeker   Tool107.  
Then,  primer  pairs  were   tested  by   in   silico  PCR  against   the   reference  human  
genome   (Hg38)   by   using   BiSearch   primer   design   and   search   tool108.   This  
software  performs   in  silico  bisulfite  conversion  prior   to  primer  design.   It  should  
be  noted  that  primer  design  is  strand  specific.  Therefore,  if  the  designed  primers  
are  complementary  to  the  DNA  reverse  strand  and  the  reverse  strand  sequence  
serves  as  an  input  data,  the  settings  of  the  software  should  remain  unchanged  
(“default-­forward  strand”)  otherwise  the  designed  primers  will  be  complementary  
to  the  forward  strand108.    
After  that,  primers  were  selected  looking  for  a  single  match  on  the  appropriate  
strand.   Primer   pairs   that   passed   the   in   silico   PCR   step   were   ordered   from  
Sigma.  Primer  pairs  were  then  validated  by  PCR  amplification  to  ensure  primers  
could   successfully   amplify   these   regions,   and   the   best   annealing   temperature  
was   chosen   for   each   pair   of   primers   with   human   genomic   DNA.   The   PCR  
reaction  consisted  of  2  μl  primer  solutions,  19  μl  of  PCR  grad  distilled  water,  25  
μl   of  Zymo  Taq  PreMix  and  2  μl   of   the   template  DNA  which  was   the  bisulfite  
converted  DNA  of  each  mixture.  The  PCR  cycles  are  listed  in  Table  2.    
Finally,  the  validated  primers  pairs  and  the  PCR  products  of  the  samples  were  
sent  for  Sanger  sequencing  at  Edinburgh  Genomics.  The  results  were  analysed  
using  the  Sequencher  5.4.6.    
4.3.3.  Sanger  Sequencing  Analysis  
Sanger   DNA   sequencing   electropherograms   allowed   the   identification   of  
methylated   cytosines,  which  would  appear  as   cytosine   in   the   traces,  whereas  
thymine  nucleotides  would  appear  in  unmethylated  cytosines.    
Quantitative  information  from  Sanger  sequencing  traces  was  obtained  by  using  
the   ab1PeakReporter  web-­based   tool109,   which   converted  Sanger   sequencing  
trace  files  into  comma  separated  value  (.csv)  files.  These  output  files  contained  
the  peak  height  and  quality  values  for  each  nucleotide  and  peak  height  ratios  for  
all  four  bases  at  any  given  locus  allowing  the  detection  and  assessment  of  small  
changes  in  methylation  at  any  given  allele.      
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4.3.4.  Primer  design  and  validation  for  Bisulfite  Pyrosequencing     
11  probes  that  showed  well-­defined  differences  in  methylation  between  tumour  
and   leucocytes   in   both   the   EPIC   array   and   the   Fluidigm   experiment   were  
selected   to   be   analyzed   by   Bisulfite   Pyrosequencing.   None   of   these   probes  
were  analysed  by  Sanger  Sequencing,  as  new  criteria  for  optimal  marker  design  
was   developed   after   Sanger   Sequencing   was   performed   during   the   Master  
project.    
Human  Genome   data  was   obtained   from  University   of   California,   Santa  Cruz  
(UCSC)   genome   database.   Human   genome   from   December   2013   assembly  
(GRCh38/hg38)  was  used  as  donor  sequence   for  primer  design.  Assays  were  
designed   using   the   PyroMark   Assay   Design   and   PyroMark   24   Software  
(Qiagen),   programs   provided   by  Dr.   Alex   Adams.   This   software   automatically  
performed   the   assay   design   including   PCR   primers   and   pyrosequencing  
primers.  The  size  of  the  amplification  product  was  restricted  to  130  bp  or   less,  
as  otherwise  secondary  structures  such  as   loops  can  be   formed   in   the  single-­
stranded  template  which  could   interfere  with  or   inhibit   the  sequencing  reaction  
or   increase   the   background   signal   due   to   the   extension   of   the   3’-­end   of   the  
terminus.  In  addition,  capture  efficiency  of  the  biotinylated  amplification  product  
decreases  with  size.    
Primers   were   designed   to   be   between   15bp   and   30bp,   with   a   melting  
temperature   (Tm)   between   60ºC   and   64ºC   and   to   avoid   CpGs   in   the   primer  
sequences.   In   addition,   the   pyrosequencing   software   incorporated   internal  






MRes in Genomics and Experimental Medicine The University of Edinburgh 
 
38 
4.3.5.  Bisulfite  pyrosequencing    
Highly   quantitative   bisulfite   pyrosequencing110   was   performed   using   the  
PyroMark  Q24  system  (Qiagen,  Valencia,  CA,  USA).  Bisulfite  Pyrosequencing  
was   performed   by   William   Hawkins   at   the   Welcome   Trust   Clinical   Research  
Facility  of  UoE.    
Each  assay  was  validated  by  means  of  a  series  of  standards  of  0,  25,  50,  75  
and   100%-­methylated   DNA.   The   standards   were   also   mixtures   created   from  
whole   genome  amplified  DNA  using   the  REPLI-­g  whole-­genome  amplification  
kit   (Qiagen),   representing   0%   methylation,   and   commercially   available   fully  
methylated   human   genomic   DNA   (Roche),   representing   100%   methylation,  
which  were  mixed   in   relative  proportions   to  create   the  same  mixtures  used   in  
Sanger   Sequencing   (Table   1).   Only   the   primer   sets   that   worked   well   in   the  
Pyrosequencing   with   the   DNA   mixtures   were   then   tested   in   five   bisulfite-­
converted   DNA   paired   samples   of   tumour   and   leucocytes,   and   four   cfDNAs  



















5.1.  Marker  Design  Optimization    
Marker  design  optimisation  was  performed   to  select   for  CpG  sites  used   in   the  
subsequent  analysis.  The  original  raw  data  from  the  Illumina  EPIC  methylation  
array   was   re-­analysed   with   the   package   minfi.   The   starting   point   of   minfi   is  
reading   the   .IDAT   files,   with   the   built-­in   function   read.metharray.   Probes  
containing  polymorphisms  and  those  with  potential  to  cross-­hybridise  were  also  
removed.   Minfi   provides   a   quality   control   based   on   the   log   median   intensity  
coming  from  CpGs   in   the  EPIC  array.  Good  samples  clustered  together,  while  
failed  samples  obtained  lower  median  intensities.  As  can  be  seen  in  figure  11,  








Figure  11:  Quality  control  of   the  samples  used   in   the  850k  EPIC  array  provided  by  
minfi  package.  All  samples  passed  the  QC  based  on  the  median  intensities  from  the  CpGs  
except  from  samples  1  and  18.  
The  data  was  normalized  by  using  Funnorm  preprocessing  method,  which  uses  
internal   control   probes   present   on   the   array   to   infer   between-­array   technical  
variation.   The   input   for   the   function   preprocessFunnorm   is   a   RGChannelSet,  
which   is   the   initial   object   for   the   analysis   containing   the   raw   intensities   in   the  
green  and  red  channels.  The  phenotype  data,  such  as  sample  names,  sample  
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5.2.  Fluidigm  Access  Array  Amplification  
5.2.1.  Primer  design  and  validation  for  Fluidigm  Access  Array  
Amplification  
Primer  design  was  performed  using  the  PrimerSuite  tool,  which  provided  a  set  
of   168   primer   pairs   targeting   23   probes   showing   differential   methylation  
between  breast  tumour  and  buffy  coat  in  the  EPIC  array.  Primer  validation  was  
performed   to  ensure   that   primer  pairs   produced  one   specific   amplifon.  Primer  
pairs   that   passed   the   in   silico   PCR   step  were   validated   by  PCR  amplification  
with  bisulfite  converted  human  genomic  DNA  (hgDNA)  to  ensure  primers  could  
successfully  amplify  the  CpGs  of  interest.    








Fugures  13A-­13I:  Agarose  gels  (1,5%  (w/v))  showing  amplicons  of  130  bp  after  PCR  
amplification  with   63  different   primers  pairs.   “+”   lanes  are  PCR  reactions  with  human  
genomic  DNA,  “-­“lanes  are  water  blanks  (negative  controls).  Figure  13I  shows  repetition  of  
five  primers  that  where   in   the   last  rows  that  may  have  been  evaporated   in   the  other  PCR  
reactions.  
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There   were   168   potential   targets   however   due   to   the   limitations   of   bisulfite  
primer   design   only   87   primer   pairs   could   be   designed   to   comply   with   the  
parameters   for   Fluidigm   amplification.   After   validation   by   in   silico   PCR,   63  
primer  pairs  were  tested  for  PCR  amplification  with  hgDNA  (Figures  13A-­13I).  A  
final  primer  set  of  23  primer  pairs  (Appendix  2)  were  chosen  in  order  to  amplify  
23   CpGs   that   showed   differential   dinucleotide   CpG   methylation   in   the   EPIC  
array.   Together  with   these,   25   primer   pairs   that   previously   amplified  CpGs   of  
interest  were  used  as  positive  controls   to  show  successful  amplification   in   the  
Fluidigm.  These  made  up  a  total  of  48  targets  to  test  on  the  Fluidigm.  
  
5.2.2.  Fluidigm  Library  and  Quality  Control  
DNA   concentrations   of   randomly   selected   Fluidigm   amplicons   were   checked  
with   Qubit   HS   dsDNA   assay   to   ensure   successful   PCR   amplification.   After  
barcoding,  another  set  of  randomly  selected  Fluidigm  samples  and  the  pre  and  
post  cleaned-­up  libraries  were  checked  with  bioanalyser  prior  to  next  generation  
sequencing  to  confirm  expected  product  size  in  each  Fluidigm  stage.  
DNA   concentrations   of   samples   increased   from   post-­Fluidigm   pre-­barcode  
stage  to  post-­Fluidigm  post-­barcode  stage.  Negligible  amount  of  amplicon  was  
generated   in  water   sample   during   Fluidigm  amplification.   The  Fluidigm   library  
concentration   was   higher   pre-­SPRI   clean-­up   than   post-­SPRI   clean-­up.   This  
indicated  successful  removal  of  non-­amplicon  DNA  such  as  primer  dimers.  DNA  
concentration  of   the   library  ranged  from  28.4  ng/μl  before  clean-­up  to  9.2ng/μl  
after  clean-­up.    
  
  















Figures  14A-­14C:  DNA  bioanalyser  traces  before  and  after  barcoding  of  the  Fluidigm  
library.   Numbers   correspond   to   matched   tumour   and   leucocyte   samples   from   breast  
cancer  patients;;  “cf”  corresponds  to  cfDNA  samples  from  healthy   individuals;;  “C”  samples  
correspond   to   barcoded   samples;;   pool   pre-­cleaned   up   and   pool   post-­cleaned   up  
correspond   to   pooled   post-­barcode   post-­Fluidigm   samples   before   and   after   the   clean-­up  
step;;   FM   and   FUM   are   the   fully   methylated   and   fully   unmethylated   DNA   controls,  
respectively  and  “w”  correspond  to  the  water  controls  used  in  the  Fluidigm.  
  
  
14A   14B  
14C  
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Bioanalysis  results  showed  the  expected  amplicon  size  in  all  random  individual  
samples   (figures   14A-­14C):   220-­250bp   in   post-­Fluidigm   pre-­barcode,   270-­
300bp   in   post-­Fluidigm   post-­barcode,   pooled   post-­barcode   post   cleaned-­up    
library  (270-­300bp).  The  four  water  blanks  showed  no  amplicon  in  post-­Fluidigm  
pre-­barcode   stage   and   the   expected   low   background   amplification   from  
barcoding  of  the  unused  primer  pairs  in  the  post  barcode  samples.  
5.2.3.  Quality  Control  of  Illumina  MiSeq  raw  data    
Amplicon   coverage,  methylated  amplicon   counts  and  CpG  methylation   counts  
were   obtained   from   paired-­end   Illumina   MiSeq   next   generation   sequencing  
(NGS)   data   analysis.   The   paired-­end   Illumina   MiSeq   dataset   consists   of   the  
sequencing  of  both  ends  of  the  same  fragment.  Therefore,  the  sequences  came  
in  two  data  files,  one  with  the  forward  paired-­end  sequences  and  one  with  the  
corresponding   reverse   paired-­end   sequences.   The   FastQC   software   provided  
assessment  of  the  quality  of   the  sequenced  bases  based  on  the  Phred  quality  
score,   which   is   logarithmically   related   to   the   probability   of   an   error   of   the  
identification   of   the  nucleobases  generated   by   automated  DNA   sequencing.   A  
score  of  10  means  a  10%  error  probability  and  30  means  a  0.1%  chance,  etc.  A  
score   of   20   is   generally   accepted   as   the   minimum   acceptable   score.   The  
FastQC   for   all   the   FastQ   files   obtained   a   high   Phred   score   over   30   or   40  
(Figures  15A  and  15B).    
  
Figures   15A,   15B:   Phred   quality   scores   of   the   raw   data   for   the   forward   and   the  
reverse  reads  of  sample  B55.  Quality  scores  across  bases  obtained  >30,  except  the  last  
bases  of  reverse  reads  due  to  the  nature  of  the  Illumina  Sequencing  platform.  
  
  
15A   15B  
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However,  reverse  reads  for  all  the  samples  obtained  lower  Phred  scores  in  the  
last   bases.   This   may   be   due   to   sequencing   by   synthesis   and   bridge  
amplification   clusters   of   the   Illumina   Sequencing   platform.   For   a   variety   of  
reasons,   including   decay   of   reagents   in   the   sequencing   machine   or   lose   of  
synchronisation  when   synthesis   of   some   templates   lags   behind   that   on   other  
templates,   errors   can   easily   be   accumulated   in   the   forming   strand   and,  
consequently,   the   quality   of   base   calls   decrease   as   sequencing   processes.  
Ultimately,  the  5’  end  of  the  reads  tend  to  have  higuer  quality  compared  to  the  
3’   ends,  and   forward   reads  have  better   quality   than   reverse   reads.  Sequence  
bases  across  the  whole  content  were  also  checked.  Taking  into  account  that  the  
Illumina  adaptors   added   for   library   preparation  were  not   bisulfite   converted,   a  
higher   percentage   of   Cytosine   was   expected   at   the   end   of   the   graph   in   the  
forward  sequences.  Inversely,  a  higher  percentage  of  Guanine  appeared  in  the  
reverse   sequences.   Moreover,   the   quality   control   showed   overrepresented  
sequences.   This   was   expected   as   the   Fluidigm   is   a   targeted   experiment,   in  
contrast  to  for  example  WGBS.  
Following  FastQC,   Trim  Galore  was   used   to   perform  adapter   trimming   in   two  
subsequent   steps.   A   second   FastQC   was   run   to   ensure   that   adaptors   were  
trimmed  based  on  the  percentage  of  cytosines  and  guanines  in  the  forward  and  
reverse  sequences,  respectively.  Trimmed  FASTQ  sequences  showed  a  higher  
percentage   of   thymine   in   the   read   ends   indicating   successful   removal   of  
adaptors.  
Next  step  involved  bismark  alignment  of  the  trimmed  FastQ  sequences  against  
the   bisulfite-­converted   Human   genome   from   December   2013   assembly  
(GRCh38/hg38).   Genome   was   bisulfite   converted   and   prepared   with   bismark  
v0.14.3   and   bowtie2.   As   primer   pairs   from   PrimerSuit   tool   were   designed   to  
amplify   the   forward  and  some  others   the   reverse  strand,   two  alignments  were  
carried   out   and   all   the   next   steps   were   performed   for   both   lists.   Bismark  
alignment   produced   SAM   files   by   default,   containing   all   the   alignments   plus  
methylation   call   strings,   and   text   files   containing   alignment,   methylation  
summaries   and   mapping   efficiency   reports.   The   total  mapping  efficiency   for  
each  sample  obtained  around  80%  and  above,  meaning   that  sequences  were  
correcly  aligned.  Water  blanks  were  expected  to  be  low,  and  the  four  obtained  
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mapping   efficiencies   ranging   from   3%   to   9%,   indicator   of   very   low  
contamination.    
SAM   files  were   the   input   files   to  obtain   the  coverage  and   the  methylated  and  
unmethylated  counts  from  all  the  sequences.  SAM  files  of  each  target  amplicon  
were   processed   (python   script)   and  BEDtools   v2.23.0  with   bedtools   coverage  
command  and  default  options   to  obtain  coverage  of  each  amplicon.  Finally,   in  
order   to   obtain   the   total  methylated   and   unmethylated   counts   per  CpG,   SAM  
files   were   also   processed   with   bismark   methylation   extractor   command   with  
paired  end  option.  Output  of  bismark  methylation  extractor  was  also  processed  
with   perl   script,   which   allowed   splitting   total   methylated   and   unmethylated  
amplicons   in   BED   files   as   output.   BED   files   were   processed   with   BEDtools  
v.2.23.0   coverage   command   to   obtain   total  methylated   and   unmethylated   per  
target  amplicons.  
Moreover,   BED   files   were   used   in   a   bedgraph   pipeline   to   obtain   methylation  
percentage  per  CpG  site.  The   last  step   involved  parsing  all   the  output   files.   In  
total,   methylated   and   unmethylated   counts   for   568   CpG   sites   (taking   into  
account   that   each   amplicon   could   contain   more   than   one   CpG   dinucleotide)  
were   obtained   across   all   48   amplicons   assayed.   Further   analysis   focused   on  
the  new  48  CpG  sites  that  were  targeted  in  the  EPIC  array.  
  
  
5.2.4.  Data  Analysis  
A.   Analysis  of  controls  coverage  
 Amplicon   coverage  of   bisulfite   sequencing  was  obtained   from   Illumina  MiSeq  
next   generation   sequencing   data   analysis   as   described   above.   Amplicon  
coverages   of   water   samples   were  markedly   lower   than   fully  methylated   DNA  
(FMD)   and   fully   unmethylated   DNA   (FUD)   controls,   though   not   completely  
absent   for   some   amplicons.   This   indicated   very   little   DNA   contamination   in  
water  samples.    
Amplicon  coverages  of  FMD  were  not  significantly  different  and  both  obtained  
more   than   ten   times   of   amplicon   coverage   of   water   samples   (Figure   16).  
Amplicon  coverage  of  the  FUM  obtained  less  reads  compared  to  the  FMD,  but  
still  has  more  than  1000  reads  when  comparing  with  the  water  controls.  As  well  
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as  showing  little  DNA  contamination,  this   indicated  successful  sequencing  and  
sequence   alignment   of   the   test   sample   amplified   DNA.   The   mean   amplicon  
coverages  of  other  samples  used  in  Fluidigm  obtained  at  least  1000  reads  more  
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Figure   16:  Heat  map  of   the   amplicon  coverage  of   the   samples.  Most  of   the  samples  
obtained   more   than   1000   reads   and   water   controls   showed   less   than   1000   reads.   “B”  
samples   represent   leucocyte   samples;;   “T”   samples   represent   tumour   samples;;   cfDNA20,  
cfDNA85,   cfDNA86  and   cfDNA87   represent   cfDNA  samples   from  healthy   individuals;;   FM  
and  FUM  are   the   fully  methylated  and   fully   unmethylated  DNA  controls,   respectively  and  
“w”   correspond   to   different   water   controls   used   in   the   Fluidigm.   Samples   and   amplicons  
that   did   not   obtain   1000   reads   and   did   not   shown   complete   bisulfite   conversion   are   not  
shown.  
  
B.   Analysis  of  samples  coverage  
Six  amplicons  that  did  not  obtain  1000  reads,  reflecting  poor  amplification,  were  
excluded,  leaving  42  out  of  the  initial  48  amplicons.  All  samples  were  applied  to  
the   Fluidigm   platform   in   replicate   as   air   bubbles   in   the   machine   can   prevent  
sample   completely   entering   the   microfluidics   chamber.   In   this   current  
experiment,   it  appears  that  this  was  the  case  for  5  sample  replicates  (samples  
B69r,  B72r,  B77r,   T41r   and  T55r)  which   had   coverage   below   the   1000   reads  
threshold.   In   addition,   one   FMD   sample   demonstrated   coverage   below   this  
threshold  and  was  also  excluded  (Figure  16).    
  
C.     Analysis  based  on  complete  bisulfite  conversion  
FUD   and   FMD   were   used   as   positive   controls   to   ensure   successful   bisulfite  
conversion.   CpGs   that   did   not   demonstrate   <10%   methylation   in   the   FUM  
control   and   >90%   methylation   in   the   FM   control   were   not   included   in   the  
analysis  (8/42  amplicons).  
  
D.   Analysis  of  Technical  Replicates  
Technical  replicates  came  from  the  same  bisulfite-­converted  DNA  sample  which  
was   analyzed   twice   by   using   two   different   wells   in   the   Fluidigm   plate.  
Correlation  analysis  was  performed  across  technical  replicates.  Table  2  shows  
Pearson’s   correlation   coefficients   of   methylation   percentages.   All   technical  
replicates   showed   a   positive   correlation   (0.83-­0.99)   indicating   that   CpG  
dinucleotide   methylation   percentage   is   reproducible   using   Fluidigm   Access  
Array   Amplification.   Samples   T66   and   T72   were   excluded   from   downstream  
analysis  as  the  experimental  replicates  did  not  correlate.    
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In   future   Fluidigm   experiments   it   would   be   useful   to   include   more   technical  
replicates,   as   their   comparison   can   be   used   to   locate   outlier   values   that  may  
occur   due   to   aberrations  within   the  Fluidigm,   the   sample,   or   the  experimental  
procedure.    
Table   2:   Pearson’s   correlation   coefficients   of   the   methylated   CpGs   obtained   with  
Fluidigm.   Two   technical   replicates   of   8   paired   samples   of   tumour   and   leucocytes   from  
breast   cancer   patients   were   included   in   the   Fluidigm   Access   Array.   Leucocyte   samples  
showed  a  very  positive  strong  correlation  whereas  tumour  samples  T66  and  T72  obtained  a  
poorer  positive  correlation.    
  
Sample   Correlation   p-­value  
B41   0.996732   2.2e-­16  
B55   0.9814165   2.2e-­16  
B66   0.9906116   2.2e-­16  
B69   0.9976815   2.2e-­16  
B72   0.9972151   2.2e-­16  
B77   0.9975796   2.2e-­16  
B82   0.9952245   2.2e-­16  
B83   0.9889942   2.2e-­16  
T41   0.8280931   2.2e-­16  
T55   0.7455518   9.413e-­16  
T66   0.1361715   0.1415  
T69   0.6398119   8.137e-­15  
T72   0.4232273   2.209e-­06  
T77   0.8311624   2.2e-­16  
T82   0.8677775   2.2e-­16  
T83   0.8741456   2.2e-­16  
  
5.2.5.  Statistical  Analysis  
E.   Normality  of  Methylation  data  
Individual   Saphiro-­Wilk   tests   were   performed   to   check   for   normality   of  
leucocyte,  tumour  and  cfDNA  samples’  distributions.  The  null-­hypothesis  of  this  
test  is  that  the  population  is  normally  distributed.  Tumour  samples  came  from  a  
normally  distributed  population  (p-­value  =  0.8948).  Leucocyte  samples  were  not  
normally  distributed   (p-­value  of  4.314e-­06).  This  was  expected  as  methylation  
levels  for  leucocyte  were  chosen  to  be  >  90%  or  <  5%  in  methylation  levels  for  





MRes in Genomics and Experimental Medicine The University of Edinburgh 
 
51 
F.   CpG  Dinucleotide  Methylation  Analysis  of  Breast  Tumour  and  
Leucocyte  Samples  
CpG   dinucleotide   methylation   status   for   30   probes   of   breast   tumour   and  
leucocyte  was  performed  by  using  Wilcoxon  signed  rank  non-­parametric  t-­test.  
Only  CpGs  that  were  also  targeted  by  the  EPIC  array  were  analysed.  All  CpG  




























Figure   17:  Differential  
Methylation   between  
paired   tumour   and  
leucocyte   samples   on  
Fluidigm   Access  
Array.  Tumour  samples  
(red  dots)  showed  clear  
differences   in  
methylation   compared  
to   leucocytes   (black  
dots).   Probes   and  
genomic   positions   for  
each   targeted   CpG   on  
GRCh38/hg38   Human  
Genome  are  provided.    
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G.  CpG  Dinucleotide  Methylation  Analysis  of  cfDNA  samples  
From  10ml  of  blood  generally  5-­50ng  cfDNA  is  recovered.  To  test  the  possibility  
that   less   than   5ng   cfDNA   can   be   successfully   amplified   on   the   Fluidigm  
platform,   amplicon   coverage   of   four   cfDNA   samples   (containing   ~5ng   cfDNA)  
was  analyzed  (Figure  18).  CfDNA20,  cfDNA85  and  cfDNA86  samples  produced  
more   than   1000   amplicon   coverage.   CfDNA87   showed   inconsistent  
amplification   for   most   of   the   amplicons   (only   10   amplicons   demonstrated  
coverage  >1000   reads).  Failure   in  amplification  of   this   cfDNA  sample  may  be  
due  to  pipetting  error   in  preparation  of  the  primer  plate  for  the  Fluidigm  assay.  
Successful   amplification   of   cfDNA20,   cfDNA85   and   cfDNA86   indicated   that  
even   at   very   low   concentrations,   the   Fluidigm   assay   can   detect   CpG  











Figure  18:  Heat  map  of   the  coverage  of  cfDNA  samples  and  water  controls.  Most  of  
the   amplicons   obtained   more   than   1000   reads   compared   to   water   controls.   Cf20,   Cf85,  
Cf86   and  Cf87   represent   cfDNA   samples   from  healthy   individuals   and   “w”   correspond   to  
different   water   controls   used   in   the   Fluidigm.   The   six   amplicons   excluded   based   on   the  
analysis  of  samples  coverage  are  included  in  this  figure.    
  
A   Wilcoxon   signed   rank   test   was   performed   to   test   whether   or   not   CpG  
dinucleotide  methylation  was  different  between  cfDNA  from  healthy  plasma  and  
tumour  samples.  As  previously  said,  only  CpGs  that  were  also  targeted  by  the  
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EPIC  array  were  analysed.  P-­values  (Appendix  4)  were  significant  for  21  CpGs  
with  an  alpha   level  of  0.05.  The  same  test  was  performed  to  compare  healthy  
plasma   cfDNA   with   leucocytes.   All   CpG   sites   across   the   genome   were   not  
differentially   methylated   (Appendix   5).   These   results   are   shown   in   figure   19,  
where   some   tumour   samples   have   similar   methylation   levels   to   those   of  
leucocytes   and   cfDNA   samples.   These   probes   will   be   excluded   from   further  
analysis.  The  remaining  CpGs  will  be  the  best  candidates  identified  in  this  study  
for  useful  biomarkers  for  early  detection  of  breast  cancer  in  an  assay  of  cfDNA  
















Figure   19:   Differential  
Methylation   Detection   on  
Fluidigm   Access   Array.  
Leucocyte   samples   (black  
dots)   showed   methylation  
percentage  of   less  than  5%  
and   more   than   95%   as  
expected.   cfDNA   samples  
(blue   dots)   from   healthy  
individuals   showed   similar  
methylation   percentages  
compared   to   leucocytes.   In  
contrast,   the   majority   of  
tumour   samples   (red   dots)  
showed  clear  differences   in  
methylation   compared   to  
leucocytes.   Probes   and  
genomic   positions   for   each  
targeted   CpG   on  
GRCh38/hg38   Human  
Genome  are  provided.    
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5.3.  Validation  of  Fluidigm  Methylation  Results  using  other  Methods    
5.3.1.  Bisulfite  Sanger  Sequencing     
H.   Primer  Pair  Validation  
Primer  pairs  from  the  nine  CpGs  shown  in  Figure  10  were  designed  for  Sanger  
sequencing   (Appendix  6)  and  were   tested   in  PCR  amplification  and  optimized  
for   six   different   annealing   temperatures:   54ºC,   56ºC,   58ºC,   60ºC,   62ºC   and  
64ºC.  PCR  products  were   visualised  under  UV   light   after   electrophoresis  with  
1,5%  agarose  gel  TBE  (0.5x)  with  10μl  SYBRSafe  per  100ml  of  gel.  Five  out  of  
nine  pairs  of  primers  successfully  amplified  bisulfite  converted  human  genomic  
DNA  and  produced  amplicons  of  around  250  bp  (Figure  20).  PCR  amplification  






     
  
  
Figure   20:   On   the   left,   agarose   gel   showing   250   bp   amplicons   corresponding   to   the   5  
validated  pairs  of  primers.  Lanes  1-­5:  primer  pairs  3.1,  2.2,  3.2,  4.2  and  8.1.  Line  6:  negative  
control  without  DNA  (NC1).  Line  7:  negative  control  without  primers  (NC2).  On  the  right,   table  
summarizing   the  melting   temperature  (Tm)  of   the  primers  and   the  best  annealing   temperature  
for  each  pairs  of  primers  obtained  in  PCR  reactions.    
  
  
I.   Validation   of   primer   pairs   in   methylated   and   unmethylated   DNA  
mixtures  
Amplification   of   10   samples,   which   were   mixtures   of   fully   methylated   and  
unmethylated   DNA,   with   two   primer   pairs   (3.1   and   8.1)   was   tested   in   PCR  
reactions.  Clear  bands  of  250bp  were  observed  for  all  the  samples  (figures  21A  



















250  bp    
amplicons  
    3.1    2.2    3.2    4.2     8.1   NC1   NC2  
 
MRes in Genomics and Experimental Medicine The University of Edinburgh 
 
55 























Figures   21A-­21B:   Agarose   gels   (1,5%)   showing   amplicons   of   250   bp   after   PCR  
amplification  of  the  10  samples  with  the  pairs  of  primers  3.1  (3A)  and  8.1  (3B).  R:  replicate;;  
lanes   correspond   to   samples   with   increasing   percentages   of   fully   methylated   and   fully  




J.   Sanger  Sequencing  Results  
The  initial  Sanger  sequences  showed  suboptimal  results  and  did  not  distinguish  
50%  fully  methylated  from  50%  unmethylated  DNA  (Figures  20A  and  20B,  show  
typical  electropherograms).  The  low  quality  of   the  sequences  might  be  caused  
by   DNA   contamination   with   mixed   templates   from   the   prepared   fully  
unmethylated  DNA,  as  some  sequences  could  have  not  been  amplified,  or  due  
to  technical  problems  during  the  sequencing.    





Figures  22A-­22B:  Sanger  sequencing  electropherograms  of  sample  4  containing  50%  of   fully  
methylated  and  unmethylated  DNA   tested  with   the  primer   pairs   8.1   (4A)   and  3.1   (4B)   for   the  
probes   cg17698295   and   cg09471455   which   contain   a   CpG   in   the   position   74   and   98,  
respectively,  on  Human  genome  from  December  2013  assembly  (GRCh38/hg38).  "Noisy"  data  

















    1     2   2R    3     4    4R   5    6     6R   7   
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    1    2   2R    3     4    4R    5     6    6R   7    
NC 
20B  
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23A   23B  
23C   23D  
  
K.   Quantification   of   Methylation   Level   in   Sanger   Sequencing   Traces   Using  
the  ab1  Peak  Reporter  Tool  
The   samples  with   the   best  Sanger   sequencing   traces   (Figures   23A  and  23B)  
were  used  to  quantify  methylation  levels.  These  samples  contained  100%,  90%,  
75%  and  50%  of  fully  methylated  DNA  and  were  sequenced  with  primer  pairs  3  
and  8.    








Figures  23A,  23B,  23C,  23D  :  Representative  Sanger  sequencing  electropherograms  
of  samples  containing  100%  (A)  90%  (B),  75%(C),  50%(D)  of  fully  methylated  DNA.    
Table   3   shows  peak  height   ratios   for   all   four   bases   obtained  using   ab1  Peak  
Reporter  tool.  Sample  S1  being  100%  methylated  showed  a  peak  height  ratio  of  
1   for   cytosine   and   the   smallest   ratio   for   thymine,   0.019.   Samples   with  
decreasing   levels   in   CpG   dinucleotide   methylation   ranging   from   100%  
methylated  until  50%  methylated  (samples  S1-­S7),  showed  a  higher  peak  ratio  
for  cytosine  at  the  same  time  that  the  ratio  for  thymine  increased  (figure  24).  
Results   showed   that  Sanger   sequencing   can  detect   fully  methylated  and   fully  
unmethylated  DNA,   however  when   samples   contained   small  methylated  DNA  
ammounts,  Sanger  sequencing  was  not  sensitive  enough.  In  addition,    technical  
replicates  did  not   indicate   reproducible  methylation  measurements  by  bisulfite  
Sanger   Sequencing.   In   conclusion,   methylation   analysis   using   Sanger  
sequencing   may   not   be   sensitive   enough   to   detect   small   differences   in  
methylation  levels.  Analysis  of  cfDNA  challenging  and  requires  highly  sensitive  
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techniques  because  of  the  small  fraction  of  tumour  specific  DNA  present  within  
background   levels   of   normal   cfDNA.   Therefore,   Sanger   sequencing   was  
demonstrated   to   not   be   an   appropiate   validation   method   for   Fluidigm  
amplification,  and  neither  appropiate  for  cfDNA-­based  tests.    
  
Table   3:  Quantification  of  methylation  of   samples  S1,  S2,  S3  and  S4  obtained  with  
ab1   Peak   Reporter   tool.   Signal   strength,   signal   strength   ratio   and  peak  height   ratios   of  
CpG   sites.   Ratio   for   thymine   gradually   increased   when   samples   had   lower   amounts   of  




Signal  Strength   Ratio  
Quality  
Value  
G   A   T   C   G   A   T   C  
S1   C   0   1   5   256   0   0.004   0.019   1   59  
S2   C   25   3   14   497   0.050   0.006   0.028   1   62  
S3   C   0   13   62   647   0   0.020   0.0958   1   43  
S4   T   0   2   133   3   0   0.015   1   0.023   27  
     
  
Figure  24:  Signal  strength  ratio  of  Thymine  and  Cytosine  of  the  samples  S1,  S2,  S3,  
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5.3.2.  Bisulfite  Pyrosequencing    
L.   Primer  Pair  Validation  
Primer   pairs   from   11   CpGs   (Table   4)   were   designed   and   validated   by   PCR  
amplification   with   bisulfite-­converted   human   genomic   DNA   (hgDNA)   and  
visualized  in  agarose  gels  as  previously  described  for  Sanger  sequencing.    
  
Table   4:   Forward   and   reverse   PCR   primers   and   sequencing   primers   designed   for  
Pyrosequencing.  Biotinylated  PCR  primers  are  marked  with  “bio”.  The  sequencing  primer  
was   designed   to   be   opposite   to   the  biotinylated  strand,   which   is   isolated   and   used   in  
sequencing  (the  non-­biotinylated  strand  is  lost  at  the  denaturation  step).    
  
Name	   Probe	   Genomic	  location	  on	  GRhg38	   Primer	  fwd	   Primer	  rev	  
18	   cg03608224	   chr12:124289407-­‐124289512	   AGTAGTTTTATTGTGGAGTGG	   CCAAATTCCCAATACTTTCAATAAATAATA-­‐bio	  
27	   cg06768993	   chr4:8441613-­‐8441737	   GGTGTTTGGAAGGTTTTAAAGAG	   ATCCCCAACACTTTTACACCTA-­‐bio	  
40	   cg11509179	   chr22:30603070	  -­‐30603219	   GGTTGTGGTATTAGGAGTTGTTAG	   TATCATTCACCTTCCAAACCTCTCT-­‐bio	  
ZIC1a	   ZIC1a	   chr3:	  147420614-­‐	  147420750	   AGGTTTTTGTGGGTTTAGTA	   AACTAAAAAACCTCTACTCCATATCTCTT-­‐bio	  
ZIC1b	   ZIC1b	   chr3:	  147420614-­‐	  147420750	   GTTGAGTTAGGTAAAGAGATATGGAGTA	   CCTTTTTTCCTACCCAAAC-­‐bio	  
*1v2	   cg00248115	   ch3:65937286-­‐65937416	   TTGGTGAGTTAGTTGGGGAAGGA	   CCTAACACTTCTCCCTTACCCTTTTAC-­‐bio	  
*2v2	   cg07222863	   chr8:103141270-­‐103141376	   GAGGAGGTGGGTTGTTTTTTTATTT-­‐bio	   AACTTCCAACAACCCAATACT	  
3v2	   cg04163216	   chr1:9717774-­‐9717904	   GAAAATAGGAAGTGGGGAGGG	   ACCCCATAACCTCCACCAAA-­‐bio	  
1v3	   cg19827883	   chr9:97993105-­‐97993238	   GTTTGGTTTTTGAAGAGGAAGTAGATA	   CAAATCAACAATACCCACAACAT-­‐bio	  
2v3	   cg27082467	   chr6:25042184-­‐25042317	   GAAGATGATGGGGAGGTAATTTATTTAAGT-­‐bio	   TACCCTCCCCCTACCATTACA	  
*3v3	   cg16260696	   chr11:67403677-­‐67403805	   AGAAATAAATAAAAGAATTGGAGGTGG-­‐bio	   CCAATAACTACAAACTTAAATTCCTATACTAATA	  
 
All  validation  assays  included  four  negative  controls:  
•   PCR  without  template  DNA,  to  test  for  non-­specific  signal  from  primer  in  
the  pyrosequencing  reactions.  
•   Sequencing  primer  without  PCR  product  (no  template  control,  NTC).    
•   Biotinylated  primer  without  PCR  product  (NTC).    
•   Sequencing  primer  and  biotinylated  primer  together  without  PCR  product  
(NTC).  
The  three  latter  NTC  were  included  to  ensure  no  secondary  structures,  such  as  
hairpins  or  duplexes,  were  contributing  to  background  signal  in  pyrosequencing  
reactions.  All  primer  pairs  successfully  produced  amplicons  of  less  than  130bp,  
as  shown  in  figure  25.  Non-­specific  background  bands  were  not  a  problem  as  
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  18  27               40   ZIC1a       ZIC1b 
  1v2         2v2   3v2        1v3 
    3v2     1v3 
only  one  primer  pair  (18)  showed  a  band  in  the  negative  control  with  the  
sequencing  and  biotinylated  primer  together.    
  
 




















Figure  25:  Agarose  gels  (1,5%)  showing  100  bp  amplicons  corresponding  
to  the  pyrosequencing  validated  pairs  of  primers:  Primers  18,  27,  40  ZIC1a  
and  ZIC1b.   “a”   lanes  are  PCR  reactions  with  human  genomic  DNA;;   “b”   lanes  
are   negative   controls   without   hgDNA;;   “c”   lanes   correspond   to   biotinylated  
primer   without   hgDNA.   “d”   lanes   correspond   to   sequencing   primers   without  
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M.  Bisulfite  Pyrosequencing  Results  
  
Using   pyrosequencing,   the   percentage   of   methylation   was   individually  
determined   at   multiple   CpG   sites   across   each   locus.   Technical   replicates   of  
three   of   the   mixtures   showed   very   low   variability   (tables   5A,   5B   and   5C),  
indicating   reliable   reproducible   methylation   measurements   by   bisulfite  
pyrosequencing.    
Tables   5A,   5B   and   5C:   Methylation   percentages   for   two   technical   replicates   for  
samples  2,  4  and  6,  containing  90%,  50%  and  10%  of  fully  methylated  DNA  obtained  
by  separate  pyrosequencing  assays.  
    
Sample  replicates  
90%   50%   10%  
Primer  set   CpG  position   2   2R   4   4R   6   6R  
ZIC1a  
Pos1   84   80   41   36   7   8  
Pos2   84   79   40   36   7   8  
Pos3   86   77   40   37   7   9  
ZIC1b  
Pos1   88   84   50   49   11   11  
Pos2   76   74   45   41   11   11  
Pos3   90   86   51   47   12   12  
Pos4   87   85   50   47   11   12  
      
Internal  controls  ensured  complete  bisulfite  conversion.  Cytosines   that  are  not  
followed   by   guanines   in   template   sequences   are   not   methylated,   and   should  
therefore  have  been  converted  to  thymine  by  bisulfite  treatment  and  PCR.  Full  
bisulfite   conversion   of   the   samples  was   confirmed   in   all   templates,   as   built-­in  








   90%   50%   10%  
Primer  set   CpG  position   2   2R   4   4R   6   6R  
18  
Pos1   83   82   39   35   8   8  
Pos2   84   85   40   36   8   9  
27   Pos1   76   76   31   30   7   7  
40  
Pos1   87   82   44   43   10   10  
Pos2   82   79   42   40   10   12  
Pos3   83   78   42   40   9   11  
Pos4   86   82   44   43   11   12  






















































Figure   26:   Representative   pyrogram   showing   complete   bisulfite   conversion   of   the  
internal  control  in  a  fully  methylated  sample  (S1).  While  the  methylated  cytosine  in  the  
CpG   (highlighted   in   blue)   showed   a   peak   for   cytosine,   no   peak   is   shown   for   the   built-­in  
quality  control  (highlighted  in  yellow)  ensuring  successful  bisulfite  conversion.  
  
Methylation  percentages   for   the  mixtures  provided  series  of  standards  (figures  
27A-­27D)   for  validation  of  assays   in   tumour  and   leucocyte   from  breast  cancer  

















Figure   27A-­27D:   Linearity   of   methylation   quantification   by   pyrosequencing.  
Methylation  scales  for  primer  pairs  27  and  40  for  different  CpG  sites  obtained  from  mixtures  
of   whole   genome   amplified   (WGA)   DNA   (expected   0%)   and   fully   methylated   DNA  
commercially  available  (expected  100%).  The  line  is  the  average  linear  regression  with  its  
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Standard  curves  allowed   to  adjust  methylation   levels   in   real  samples   for  each  
assay.  Methylation  levels  were  successfully  assessed  in  five  paired  tumour  and  
leucocyte   samples,   and   in   four   cfDNA   samples.   Statistical   analysis   was  
performed  to  assess  differences  in  methylation.  Bartlett   test  was  significant  for  
homogeneity  of  variances  therefore  individual  t-­tests  with  an  alpha  of  0.05  were  
performed.  Tumour  samples  were  significantly  different   from   leucocytes   (table  
6A)  and  cfDNAs  samples  (table  6C),  whereas  leucocytes  and  cfDNAs  were  not  
significantly  different  with  an  alpha  level  of  0.05  (table  6B).    
  
Tables  6A,  6B  and  6C:  Statistical  analysis   for  pyrosequencing   results.  Significant  p-­
values   were   obtained   for   tumour-­leucocyte   comparisons   and   for   tumour-­cfDNA  









Means  of  methylation  percentages  were  calculated.  Overall,  methylation  levels  
in   tumour   samples   ranged   from   18%   to   80%,   from   1%   to   5%   in   leucocyte  
samples,   and   from   1%   to   10%   in   cfDNA   samples   from   healthy   individuals.  














CpG	   P-­‐value	  
2v2_pos1	   0.026798	  
2v2_pos2	   0.031498	  
2v2_pos3	   0.013166	  
3v3_pos1	   0.000253	  
3v3_pos2	   0.000182	  
Leucocytes-­‐cfDNAs	  
comparisons	  
CpGs	   P-­‐value	  	  
2v2_pos1	   0.180597	  
2v2_pos2	   0.792534	  
2v2_pos3	   0.691964	  
3v3_pos1	   0.110162	  
3v3_pos2	   0.094493	  
Tumour-­‐cfDNAs	  
comparisons	  
CpGs	   P-­‐value	  	  
2v2_pos1	   0.028176105	  
2v2_pos2	   0.029706425	  
2v2_pos3	   0.011206465	  
3v3_pos1	   8.25E-­‐05	  
3v3_pos2	   3.62E-­‐05	  
















Figures  28A  and  28B.  Representative  pyrosequencing  results  for  probe  cg07222863.    
28A,  Box  plot  of  methylation  means  in  paired  leucocyte  (1)  and  tumour  (2)  samples,  and  in  
cfDNA  samples   (3)   reported   for   probe   cg07222863  by   pyrosequencing.   Tumour   samples  
obtained   a   mean   of   methylation   percentage   of   38.27168,   leucocytes   of   4.200885   and  
cfDNAs  of   5.14115.  28B,  Comparisons   of   dinucleotide  methylation   percentages   for   three  
CpG   sites   contained   in   probe   cg07222863   between   paired   tumour   (blue   hue)      and  
leucocyte   samples   (red   hue),   and   cfDNAs   (grey   hue)   from   healthy   people   reported   by  
pyrosequencing.   Numbers   69,   72,   82,   84   and   86   represent   different   leucocyte   samples;;  
same   numbers   ended   with   a   “T”   represent   their   paired   tumour   samples;;   and   cfDNA20,  



































69 72 82 84 86 69T 72	  T 82T 84T 86T cfDNA20 CfDNA85 CfDNA86 CfDNA87
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5.4.   Correlation  of  CpG  Dinucleotide  Methylation    
Correlations   between   assays   were   assessed   by   linear   regression   and   by  
Pearson's   correlation.   Correlation   plots   were   prepared   to   investigate   the  
agreement   between   the   2   assays.   Statistical   analysis   was   performed   using  
Tukey(HSD)  and  P<0.05  was  considered  statistically  significant.    
This   variability   in   tumour   samples   is   shown   in   the   correlation   plot.   Tumour  
samples   show   a   weak   correlation   of   methylation  measurements   between   the  
EPIC   array   and   Fluidigm-­MiSeq   (R2=   0.649948)   whereas   leucocyte   samples  
correlated   significantly   better   (R2=   0.993984)   between   the   two   methods.  
Overall,   significant   linear   associations   were   observed   for   methylation  




Sample   Correlation   Adjusted    
p-­value  
B41   0.9971536   2.2e-­16  
B55   0.9943155   2.2e-­16  
B66   0.9979749   2.2e-­16  
B69   0.9815363   2.2e-­16  
B72   0.9959881   2.2e-­16  
B77   0.9935976   2.2e-­16  
B82   0.9966643   2.2e-­16  
B83   0.9952834   2.2e-­16  
B84   0.9978038   2.2e-­16  
T41   0.8497082   2.86  e-­09  
T55   0.7671869   7.586e-­07  
T66   0.1698525   0.3695  
T69   0.5950708   0.0005233  
T72   0.3833564   0.03651  
T77   0.1982793   2.2e-­16  
T82   0.4351883   0.01624  
T83   0.6837339   3.111e-­05  
T84   0.8092882   6.158e-­08  
  
Table  7:  Pearson’s  correlation  coefficients  of  the  methylation  levels  reported  by  EPIC  
and   Fluidigm-­MiSeq.   Leucocyte   samples   showed   a   very   positive   strong   correlation  
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An   analysis   of   Variance   (ANOVA)   was   used   to   compare   methylation   means  
reported  by  Fluidigm-­MiSeq,  EPIC  array  and  pyrosequencing.  Homoscedasticity  
was  verified  performing  Bartlett  test  (P  value  =  0.9593).  Then,  a  p-­value  >0.05  
was   obtained   for   analysis   of   variance.   This   indicated   that   the   three   different  
methods  were  statistically  equal  in  detecting  methylation  levels  (figures  31A  and  
31B).  A  TukeyHSD  posthoc   test  was  performed   to  obtain  detailed   information  
about   mean   differences   in   all   possible   simple   contrasts.   Any   of   the   three  


















Figure   31A   and   31B.   31A,   Box   plot   showing  means  of  methylation   levels  measured  by  
Fluidigm   (green),   EPIC   array   (orange)   and   pyrosequencing   (blue).   31B,   Comparison   of  
methylation   percentage   reported   by   the   three   methods   for   probe   cg16260696   which  
contains   a   differentially   methylated   CpG   in   chr11:67403729   position   on   GRCh38/hg38  
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6.   CONCLUSIONS  
Tumour,   leucocyte  and  cfDNA  samples  had  been  successfully  analyzed  using  
the   Fluidigm   Access   Array   Amplification   and   Illumina  MiSeq  Next   Generation  
Sequencing.  Twenty-­three  different  primer  pairs  were  designed  and  validated  to  
specifically  amplify  CpG  sites   that  showed  extreme  methylation  distribution   for  
leucocytes  with  a  methylation  difference  of  >  20%  in  the  tumour  samples  in  the  
EPIC   array.   Sixteen   of   the   twenty-­three   CpGs   passed   all   the   filtering   criteria  
after   the   MiSeq   Sequencing   analysis,   and   showed   significant   differences  
between  tumour  and  buffy  coat.  Methylation  levels  between  cfDNA  from  healthy  
individuals  and  tumour  samples  were  statistically  different.    
EPIC   and   Fluidigm-­MiSeq   showed   moderate   positive   correlation   overall,   but  
showed   strong   positive   correlation   for   leucocyte   samples,   the   latter   being  
selected    to    have  extreme  methylation  levels  for  marker  design.  
Regarding  the  validation  methods,  pyrosequencing  showed  to  be  more  accurate  
than  Sanger   sequencing,   which  may   not   be   sensitive   enough   to   detect   small  
differences   in   methylation   levels.   Pyrosequencing      showed   high   sensitivity  
reliably   detecting   10%,   25%,   50%,   75%   and   90%   of   methylation.  
Pyrosequencing   also   showed   reproducible   correlation   across   technical  
replicates   with   different   ratios   of   methylated   DNA.   In   contrast,   Sanger  
Sequencing   while   successfully   detecting   100%   methylated   and   100%  
unmethylated  DNA,  could  not  detect  small   levels   in  methylation,   in  addition   to  
showing  detection  bias  towards  methylated  DNA.    
In   conclusion,   target-­specific   marker   design   optimization   allowed   detection   of  
methylation  differences  between  tumour  and  leucocyte  samples,  and  in  addition  
showed  potential   for  detection  of  methylation   in   cfDNA  with   the  48.48  Access  
Array.  Pyrosequencing  supports  these  results,  and  is  therefore  a  useful  method  
for      validation   of   Fluidigm-­MiSeq   methylation   data.   These   techniques   used  
together  may  have  the  potential  to  ultimately  translate  methylation  patterns  from  
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7.   DISCUSSION  
Liquid   biopsies   are   non-­invasive   methods   for   detection   and   monitoring   of  
cancer-­associated   alleles   and   likely   to   substitute   traditional   tissue   biopsies   in  
the   future.  Most  studies   focus  on   the  detection  of  somatic  mutations   in  cfDNA  
and   have   already   obtained   high   levels   of   sensitivity   for   cfDNA   biomarkers   in  
different  metastasic  cancer  types111.  In  addition,  the  feasibility  of  using  tumour-­
specific   mutations   in   cfDNA   to   monitor   the   response   to   therapy   has   been  
demonstrated   in   colorectal112,   breast73,   ovarian113   and   lung73   cancers.   While  
effective,  this  approach  was  found  to  be  time  consuming78,  and  difficult  to  apply  
to   an   extended  patient   population   given   the   highly   individual   profile   of   cancer  
mutations67.    
  
Methylated  cfDNA  has  also  been  reported  as  a  marker  of  surgery,  for  instance  
Liggett  and  colleagues  found  methylated  sequences  in  plasma  of  breast  cancer  
patients   that   decreased   following   surgery   and   tamoxifen   treatment114.   In  
addition,   gene  methylation   patterns   of   both   individual   genes  and  gene  panels  
have  been  correlated  with  patient  survival115. The  present  study  aimed  to  find  a  
set   of  CpG   sites   from  a   preliminar  methylation   study   using   the   Illumina  EPIC  
Methylation   Array,   which   interrogated   CpG   dinucleotide   methylation   at   over  
850,000  DNA  sites.  A  total  of  3172  CpGs  showed  clear  methylation  differences  
between   tumour   and   leucocytes   of   patients  with   breast   cancer.   48  CpG   sites  
showing  marked  methylation   differences   were   used   in   this   study   to   establish  
accurate   and   reliable  methods   for   CpG   dinucleotide  methylation   detection,   to  
ultimately  be  translated  into  an  assay  applicable  to  circulating  tumour  DNA.  All  
tumour,  leucocyte  and  cfDNA  samples  used  for  this  purpose  were  successfully  
amplified   with   the   Fluidigm   Access   Array   followed   by   Illumina   MiSeq  
sequencing.   This   approach   has   provided   accurate   methylation   percentages,  
which  demonstrate  high  correlation  with  the  EPIC  array  methylation  values.  
  
Several  other  approaches  have  recently  been  proposed  for  non-­invasive  cancer  
detection,  and  potential  epigenetic  aberrations  have  been  shown  to  differenciate  
healthy   plasma   from   tumour   in   breast   cancer   patients116,117,118,119.   However,  
these  techniques  mostly  used  the  candidate  gene  approach  and  did  not  rely  on  
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detecting   specific   biomarkers   to   certain   tumour   types.   Importantly,      Kang   and  
colleagues   proposed   the   CancerLocator   method   to   infer   the   proportion   and  
tissue   of   origin   of   cfDNA   in   a   blood   sample   using   genome-­wide   DNA  
methylation   data.   Whole-­genome   bisulfite   sequencing   data   is   an   increasingly  
used   technique   for   methylation   studies   that   is   allowing   the   constructuion   of  
genomic-­maps  at  single-­base  resolution  of  nearly  every  CpG  site,  including  low  
CpG-­density   regions.   Other   experimental   approaches   for   DNA   methylation  
include  enzyme  digestion,  affinity  enrichment-­based  methods,  methylated  DNA  
immunoprecipitation   (MeDIP)120,   methylation   arrays   and   commercial   DNA  
methylation   kits.   In   addition,   emerging   thrid-­generation   sequencing  
technologies,   including   single-­molecule   real-­time   sequencing   (SMRT)   and  
Oxford   Nanopore   technology,   are   being   adopted   in   epigenetics   research.  
Furthermore,   bisulfite   conversion   sequencing   can   be   done   with   targeted  
methods   such   as   amplicon   methyl-­seq,   target   enrichment,   or   with   whole-­
genome  bisulfite  sequencing  (WGBS).  Additionally,  OxBS  and  TAB-­Seq  can  be  
used  with  NGS   for   identification   of   hydroxymethylation   (5-­hMc)   in   conjunction  
with   methylation   (5-­mc)   analysis.   Research   questions,   cost,   amount   of   input  
DNA   and   the   exprected   degree   of   methylation   changes   are   the  main   factors  
when   selecting   a   particular   technique.   Validation   methods   used   in   this   study  
were   the   most   cost-­effective   and   practical   for   medium-­throughput   analysis.  
Methylation   analysis   using   Sanger   sequencing   has   not   been   not   sufficiently  
sensitive   to   accurately   detect   small   differences   in   methylation   levels.   While  
Sanger   sequencing   did   reliably   detect   100%   fully   methylated   and   100%   fully  
unmethylated  DNA,  it  was  not  possible  to  distinguish  50%  fully  methylated  DNA.  
Low  quality  of  the  sequences  may  be  improved  by  additional  cleaning  steps  in  
the   FUD   preparation.   However,   Sanger   sequencing   may   not   be   sensitive  
enough   when   aiming   to   establish   a   reliable   method   for   detection   of   small  
changes  in  methylation.    
In   contrast,   pyrosequencing   has   provided   both   quantitative   and   qualitative  
methylation   data   and   the   results   have   demonstrated   that   small   changes   are  
detectable   in   both   the   mixtures   and   breast   tumour,   leucocyte   and   cfDNA  
samples.  In  addition,  methylation  levels  in  paired  tumour  and  leucocyte  samples  
reported  by  this  technology  correlate  well  with  both  the  Fluidgm  and  EPIC  array  
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data.  Therefore,  pyrosequencing   is  reproducible,  and  also  works  with  very   low  
concentrations   of   DNA.   In   conclusion,   Fluidigm   amplification   and  
pyrosequencing   together   can   be   used   to   accurately   detect   methylation   in   an  
assay  of  cfDNA  obtained  from  blood.    
The   results   described   above   were   obtained   by   first   selecting   a   methylation  
pattern  in  breast  tumour  samples  which  was  distinct  from  the  patterns  shown  in  
leucocytes   in  the  EPIC  array,   then  determining  whether  that  same  methylation  
level   was   obtained   using   Fluidigm   amplification.   In   agreement   with   previous  
research,  methylation  levels  between  cancer  samples  and  paired  normal  tissue  
have   shown   different   patterns   of   methylation   with   our   methodology.    
Specifically,   breast   tumour   samples   demonstrated   different  methylation   levels  
compared  to  those  in  their   leucocyte  paired  samples  and  cfDNA  samples  from  
healthy  individuals.  On  the  other  hand,  tumour  samples  showed  a  lower  positive  
correlation   in   methylation   levels   than   leucocyte   samples   between   Fluidigm-­
MiSeq   and   EPIC.   The   EPIC   array   bisulfite   conversion   was   done   using   a  
different   bisulfite   conversion   kit   (Epitech),   which   could   have   led   to   different  
fragmentation  and  different  levels  of  incomplete  bisulfite  conversion.   
Methylation   of   CpG   sites   at   selected   DNA   sequences   provides   a   level   of  
regulation  over  gene  expression.  Genome  methylation  undergoes  coordinated  
changes   at   defined   stages   of   development   and   in   response   to   environmental  
stimuli   such   as   diet,   chemical   toxins   and   pollutants,   and   temperature  
stresses121.   Compared   with   other   cancer-­specific   biochemical   modifications,  
methylation  of  DNA  is  a  cancer-­specific  stable  modification  that  can  be  obtained  
from  diverse  body  fluids,  including  whole  blood122,  plasma123,  circulating  tumour  
cells124,   serum125,   saliva126,   urine127,   bronchoalveolar   lavage128,   sputum7,  
stool129,   and   fine   needle   aspirate130.   These   features   make   CpG   dinucleotide  
methylation  a  suitable   target   for  alternative  non-­invasive  diagnostic   strategies.  
Additionally,   the   number   of   aberrantly   methylated   CpG   sites   is   significantly  
larger   than   the   number   of   genetic   mutations.   This   allows   for   a   more   flexible  
design   with   a   larger   number   of   diagnostic   targets.   Methylated   cfDNA   is   a  
challenging  substrate  to  work  with,  largely  because  cfDNA  is  highly  diluted,  with  
concentrations  as  low  as  <  10  ng  per  ml  of  plasma  in  healthy  subjects131.  What  
is   more,   the   methylated   component   is   an   even   smaller   subfraction   of   this  
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amount.  Thus,  many  of  the  technical  issues  for  this  study  relate  simply  to  limited  
quantities  of  starting  material.  Generation  of  PCR  duplicates  could  have  had  an  
impact  on   the  results.  PCR  errors   in  early  stages  of  amplification,  especially   if  
occur   at   CpG   of   interest   could   have   affected  methylation   results.   In   addition,  
PCR   duplicates   might   have   affected   methylation   estimation.   In   this   case,   it  
might   be   useful   to   estimate   the   number   of   starting   material   as   input   for   the  
Fluidigm.   This   issue   can   also   be   addressed   by   the   incorporation   of   Unique  
Molecular   Identifiers   (UMIs).   Moreover,   another   of   the   major   concerns   is   the  
lack  of  standardised   techniques.  Collection  and  processing  of  clinical  samples  
needs   to   be   even   more   carefully   considered   for   discovery   and   validation   of  
circulating   biomarkers.   Blood   in   EDTA   tubes   can   only   be   stored   for   a   limited  
amount  of  time  before  leucocytes  start  to  lyse,  and  genomic  leucocyte  DNA  will  
therefore   be   contributing   to   the   plasma   DNA   fraction.   In   addition,   bisulfite  
conversion,  used  as  the  gold  standard  method  for  assessing  DNA  methylation,  
fragments   the   DNA   resulting   in   lower   input   for   Fluidigm   amplification.   In  
addition,  a  high  sequencing  depth  is  required  to  differentiate  real  modifications  
from  background  sequencing  errors.    
Another   challenge   in   cfDNA   studies   is   that   many   aspects   of   the   biological  
characteristics   are   still   not   clear.   For   instance,   the   size   of   cfDNA   has   been  
shown   to   be   variable   (70bp-­200bp)70,   though   Lo   and   colleagues   previously  
showed   a   characteristic   size   pattern   at   166bp132.   In   this   study,   an   amplicon  
length  between  125  and  135  bp  was  successfully  amplified  in  cfDNA  samples,  
obtaining  more  than  30,000  reads,  and  methylation  levels  have  been  detected.  
The   size   of   cfDNA   reflects   the   apoptotic   origin   of   the   DNA83.   A   technical  
consequence   of   this   is   that   DNA   purification   methods   are   not   as   efficient   at  
extraction   of   cfDNA,   leading   to   possible   DNA   losses.   Furthermore,   cfDNA   is  
known  to  be  found  in  a  background  of  non-­tumour  cfDNA,  derived  primarily  from  
apoptosis  of  normal  cells  of  the  hematopoietic  lineage  133,100,75,134.  Our  working  
hypothesis  was  based  on  this  assumption.  Nevertheless,  the  characterization  of  
aberrant   DNA   methylation   patterns   depends   on   a   normal   reference   DNA  
methylome.  Since  each  cell   type  presents  a  specific  DNA  methylation  pattern,  
defining  a   reference  DNA  methylome   is   still   a  major   challenge.  However,   this  
study   anticipates   that   methylation   levels   in   leucocytes   from   breast   cancer  
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patients   can   be   compared   to   those   obtained   in   healthy   cfDNAs.   Hence,    
methylation  levels  in  non-­tumour  circulating  DNA  assumed  to  come  mainly  from  
leucocytes  could  serve  as  a  reference  methylome  to  detect  aberrant  epigenetic  
events  when  comparing  with  cfDNA  in  breast  cancer  patients.    
Regarding  marker  design   for   this  study,  probes  having  extreme  beta-­values   in  
leucocyte  samples  in  the  EPIC  that  intersected  best  q-­value,  median  differences  
and  widest  beta-­value  separation  between  tumour  and  leucocyte  samples  were  
chosen  to  be  tested  with  the  Fluidigm-­MiSeq  assay.  Determining  the  specificity  
of  a  biomarker  requires  large  numbers  of  healthy  controls,  ideally  age-­matched  
and   collected  within   the   same   setting   and   in   cancer   patients   as  well   as   from  
healthy  control  population.  As  noted  above,  a  normal  reference  DNA  methylome  
is  required,  but  healthy  samples  are  also  likely  to  show  changes  in  methylation  
due  simply  to  the  presence  of   inflammation  or  after  exercise135.  Consequently,  
the   resulting   biomarker   may   not   be   able   to   differentiate   between   cancer   and  
other   physiological   conditions   with   an   inflammation   component.   Presumably,  
the  establishment  of  an  extreme  threshold  in  methylation  levels  (less  than  5%  or  
more   than   95%)   of   leucocyte   samples   may   have   included   this   variability   in  
methylation   as   well   as   modifications   coming   from   other   physiological  
circumstances.    
A  limitation  of  this  study  is  the  small  number  of  paired  samples  studied  (n=10)  
as  well  as  cfDNA  samples  (n=4).   In  order   to  consistently   translate  methylation  
patterns  from  tumour  to  cfDNA,  future  research  should  include  greater  numbers  
of  samples.  This  could  enable   full  evaluation  of   the  potential  and   limitations  of  
this   approach.   Expanding   the   breadth   and   quality   of   the   healthy   reference  
datasets   to   explore   the   distribution   of  methylation   patterns   in   leucocytes   from  
heathy  people  is  likely  to  robustly  identify  more  specific  markers.  For  instance,  
the   identification   of   CpGs   where   methylation   levels   vary   depending   on   other  
physiological  conditions   in  healthy   leucocytes  will  avoid   incorrect  comparisons  
that  could  lead  to  false-­positives.    
  
In  summary,  low  concentrations,  small  size  of  cfDNA,  and  technical  issues  can  
be  problematic  in  methylation  studies  and  need  to  be  overcome  for  methylation  
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of  cfDNA  to  be  used  in  the  clinical  setting  as  a  cancer  biomarker.  Despite  these  
difficulties,   this   study   demonstrates   that   cfDNA   from   healthy   samples   can   be  
amplified   and   investigated.   These   initial   results   are   encouraging   and   further  
optimisation  will   allow   liquid   biopsies   to   be   routinely   applied   into   the   clinic   for  
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8.  FUTURE  DIRECTIONS  
Even  though  sequence  events  play  a  critical  role  in  aberrant  gene  expression  in  
cancer,   studying   them  alone   remains   insufficient   to  understand  how  genomes  
are   translated   into   transcriptional   patterns   in   normal   and   cancer   cells.  
Therefore,  epigenetics  has  emerged  as  a  critical  process  in  cancer  progression,  
together  with  genetic  events.  The  increasing  interest  in  this  field  has  allowed  the  
development  of  sensitive  platforms  to  detect  events   that  are  now  known  to  be  
involved   in   many   diseases.   Aberrant   epigenetic   events   are   frequent   in   early  
stages   of   cancer41.   Thus,   epigenetic   alterations   may   have   the   potential   to  
become  biomarkers  for  diagnostics,  stratification  and  prognosis.    
Tissue-­tumour  profiles  are  subject  to  sampling  bias  and  provide  only  a  snapshot  
of  tumour  heterogeneity,  hence  missing  the  clonal  composition  of  each  tumour  
as  a  whole,  and  cannot  be  obtained  repeatedly.  In  contrast,  genomic  profiles  of  
circulating  cell-­free  tumour  DNA  overcome  tumour  heterogeneity  and  can  detect  
changes   that   come   from   both   primary   and  metastasic   tumours.  CfDNA   offers  
the   possibility   to   detect   specifically   what   kind   of   molecular   changes   are  
happening  in  the  tumour  in  real  time.  
CfDNA  has  an  enormous  potential  as  a  “liquid  biopsy”  and  the  results  obtained  
in  this  project  suggest  several  translational  implications  and  important  avenues  
for   future   research   when   bigger   datasets   are   explored.   A   limiting   step   in   the  
analysis  of  cfDNA  is  the  minute  amounts  of  cfDNA  available  from  the  plasma  of  
cancer   patients   and/or   healthy   volunteers.   However,   Fluidigm   MiSeq-­
sequencing  and  pyrosequencing  have  both  detected  methylation  in  cfDNA  from  
healthy  plasma  and  have  shown  a  very  positive  strong  correlation  when  using  
paired  tumour  and  leucocyte  samples.      
In   conclusion,   these   2   methodologies   used   and   developed   in   this   Masters  
project  show  evidence  of  their  potential  utility  and  that  of  epigenetic  analysis  of  
cfDNA   for  detection  of   tumour-­derived  cfDNA   in  patients   that  can,  with   further  
work,  be  useful  in  clinical  practice.  
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Appendix  1:  Principle  of  Sanger  Sequencing  and  Pyrosequencing  
Pyrosequencing   uses   a   high-­throughput   platform   that   can   interrogate   many  
CpG   sites   within   an   amplicon   in   real   time.   The   pyrosequencing   platform   is  
designed   to   detect   single-­nucleotide   polymorphisms,   or   SNPs,   which   can   be  
artificially  created  at  CpG  sites  through  bisulfite  modification,  as  the  two  strands  
of  genomic  DNA  are  no   longer  complementary  as  unmethylated  cytosines  are  
deaminated   to   uracils,   which   do   no   longer   base   pair   with   the   unmodified  
guanine   in   the   formerly   complementary   strands.   Assuming   that   methylation  
occurs  consistently  in  both  strands  around  the  CpG  analyzed,  both  strands  can  
be   used   for   pyrosequencing   amplification   assuming   that   methylation   occurs  
consistently  in  both  strands  of  a  CpG  site.    
This   technology   is   distinct   from   Sanger   sequencing,   in   which   normal  
deoxynucleotides   and   labeled   dideoxynucleotides   (ddNTPs)   are   incorporated  
randomly   in   the   reaction.   The   latter   terminate   DNA   strand   elongation.   These  
chain-­terminating  nucleotides   lack  a  3'-­OH  group   required   for   the   formation  of  
a  phosphodiester   bond  between   two   nucleotides,   causing  DNA   polymerase   to  
cease  extension  of  DNA  when  a  modified  ddNTP  is  incorporated.  The  ddNTPs  
may   be   radioactively   or  fluorescently  labeled   for   detection   in   automated  
sequencing   machines.   As   a   result,   extension   of   strands   is   representative   of  
each   nucleotide   position;;   rather,   pyrosequencing   uses   a   sequencing-­by-­
synthesis   system   in   which   nucleotides   are   dispensed   one   at   a   time,  








Figure  9:  Enzyme  cascade  system  in  pyrosequencing  (Modified  from  Qiagen).  First,  a  
bisulfite-­converted   DNA   segment   is   amplified   via   PCR   with   one   of   the   primers   being  
biotinylated.  After   denaturation,   the  biotinylated  single-­stranded  PCR  amplicon   is   isolated  
and   incubated   with   a   sequencing   primer   and   the   enzymes   DNA   polymerase,   ATP  
sulfurylase,  luciferase,  and  apyrase,  as  well  as  the  substrates  adenosine  5'  phosphosulfate  
(APS)  and  luciferin.  After  successful  incorporation  of  a  nucleotide  by  DNA  polymerase  into  
the   growing   DNA   strand,   PPi   is   released     and   reacts   with   APS   in   the   presence   of   ATP  
sulfurylase   giving   rise   to   ATP.   ATP   in   the   presence   of   substrate   luciferin   and   enzyme  
luciferase   produces   oxyluciferin   that   generates   visible   light,   which   can   be   detected   by   a  
charge  coupled  device  (CCD)  and  seen  as  a  peak  in  the  raw  data  output  (Pyrogram).  Any  
unincorporated   nucleotides   and   ATP   are   degraded   into   its   building   blocks   by   enzyme  
apyrase   prior   to   the   next   nucleotide   dispensation.   Addition   of   dNTPs   is   performed  
sequentially,   allowing   the   complementary   DNA   strand   to   be   built   up   and   the   nucleotide  
sequence   is   determined   from   the   signal   peaks   in   the   Pyrogram   trace.   ATP  (adenosine  
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Appendix   2:   List   of   designed   48.48  Fluidigm  Access  Array  Primer  pairs.  
Green   background   primer   pairs   are   targeting   23   unique   probes   and   orange  
background  primer  pairs  were  used  as  positive  controls.    
Probe	   Forward	  sequence	   Reverse	  sequence	  
cg00017461	   AATACCCTTCCTACCCTCT	   GGGGGATGTTGGTTTTGG	  
cg00911290	   GGTAGGTAGGGGAAAAGG	   CTAACCCCCAAAAACCACA	  
cg02184606	   AAAATATTTCCTTCCTCCTCC	   ATGTTTTTTGTTTTGTTTTTAGTTGT	  
cg07481320	   AAAAAAAAACCCCTCCCCC	   AAATAAAAAGAAATTAGAGTAGTTAAAA	  
cg12435154	   CTACAACACCACCTCCAC	   TTTGTGTTTTTATGTTTTGTTTTTGA	  
cg17518965	   CATTATTCTACACTACAACCAC	   TTAGTAAGTTTTTTAGTATTATTAGG	  
cg22331159	   TGGAGGTTTAGGGTGGGT	   ATAAATAAACCAAAAAAATAATTCTTCT	  
cg26680502	   ATCTCAAAAAAACAACCCCTATC	   TATTATTTTTTTTTTTTGGAAAGAAGG	  
cg02082674	   AAAAAAAATACCAATACCCTAAACCTACTT	   GGTGTTTTTTTAGATGGGTTTATGAGG	  
cg03236137	   GATATAGTTTAGTTTTTAAATTGTGTTAGAGA	   CTAAACACTCCTTATATCCCAACCA	  
cg08556894	   GTGTGTGAGTTTAATTGTTAAAGAGGA	   CCTATACTATTATCAATAAATTTTTTACCAAC	  
cg09034874	   AACCACCTTCCCCAAATTCCTATTT	   TTATTTTTTTTAGTTTTGTGTTTTTTGGATAAGA	  
cg16260696	   ATTTTGTTTTAAAAGAAATAAATAAAAGAATTGGAG	   TCCCACCTTCCCCATAACCC	  
cg19827883	   AAGAAAAGTGGAAGGAAGGAAGAAG	   TTCAAATCAACAATACCCACAACATAATAA	  
cg21777700	   TAGAGTTTTTTATGTAAGATGTTATTATGAGA	   TATTTTTAAAATATAATAAAAAAAAACTCACCACC	  
cg25534244	   AAACCTACAACTCAAAACAAAAAAACACTT	   AGGAGAGGGTTGTAAGAGAGGA	  
cg26427109	   TAACTCTTCCACTTCCCTTCTTCTT	   GTTTGTGTTGGGAGTTTATTTATTTAGG	  
cg03195881	   CCAATAAAACTAAAAATTTTTCTTTC	   GGTTAGGTTTGGTAGGAGG	  
cg15853475	   TTTTGTTGAATTTAGTGTTATTTTATAG	   ACCCACCTTAACCTCCCA	  
cg27082467	   TGTTTTAGTTTTTTGTGTTATGTTTT	   CACCTACCCTCCCCCT	  
cg07222863	   YGGATTAGGGGGTGGGTGGTTGAG	   CCCCAACTTCCAACAACCCAATACTC	  
cg09489894	   TTAGGAGGGTGAAGTTAGAGGATGATGTG	   AACCRTATTCTCTTACCTCCTTCCTAATCC	  
cg11509179	   TTAGGAGGYGGGAATGTAGAGAATGTGG	   ACACCTATCRTCCCAAACCCTTAACAAAC	  
cg13656001	   AGGATAGGGTTGGGAAGGAAATAGGAAG	   CCCTCTACAAATCTTCTCCAATCTTTCCCC	  
cg14533732	   ATTAGTAGAGGAGTAAAGGGGTGTTGGAG	   ATTCCCAATTCAACAACAACCTACCTTTCC	  
MCF2L2_rc2	   GTGTAGGGGAGGGATTTAGGAAGAAGTTTATAAG	   TACAAACACACAAAAAAAACTACACCCACAAC	  
IKZF1_rc2	   GGTTAGGTTAGGGAAGAGTTAGGGATAGGTTG	   AAAAATATTCCACCTCCCCTCTTCAACATTAC	  
ZIC1_c	   TTGTTGGGTTTTTGGGATGAGAATTTGGG	   CAATCCTTCCCCCTCCCTCCAACTC	  
SOX14_a	   AATTTGAAGGGTTAGGTTGGAAAGGGG	  TACGGTAGCAGAGACTTGGTCTRCACCCTAATTTCCTAATTCCCCATCTAAACC	  
cg00248115	   TTGGTGAGTTAGTTGGGGAAGGAGAGG	   ACCCCACCCTAACACTTCTCCCTTACC	  
cg01259145	   GGGGGAATAGAGGTTAGGGTGGAG	   CAACCTCATCCTCTCTCCCCCTACC	  
cg01314252	   AATGTTTTATGAAGGGGAGGAAGTTGTGGG	   AAAAAAAACRAACCCCACACACTAACC	  
cg03598297	   GGTTTYGGAGTTGTTGTAGGGTGG	   TAACACRCAATTTTTCCCAAAACCTTCC	  
cg03608224	   GGGGTTGYGGGAAAGTTAAGTTAGG	   TACRTATCCAAAACAACCTCCAAATTCCC	  
cg04163216	   GGTTTGAAAATAGGAAGTGGGGAGGGGG	   CCCTAAACTAAACCTAACCCCATAACCTCC	  
cg06768993	   AAGATGGGATAATTGATTGGGGTGGTG	   TCCCCAACACTTTTACACCTACAACTTTAC	  
cg06966839	   YGTGGGGGGTTTTTGAGGATAGGG	   TCCACCCCCTCTCCTTATTACATCATAACC	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Appendix  3:  Adjusted p-values obtained from a Wilcoxon  signed  rank  test  
between  paired  tumour  and  leucocyte  samples.  Paired  t-­tests  are  a  form  of  
blocking,  and  have  a  greater  power   than  unpaired   tests  when  the  paired  units  
are  similar  with   respect   to   “noise   factors”   that  are   independent   in   the  different  
groups   being   compared.   That  way   the   correct   rejection   of   the   null   hypothesis  
can  become  much  more  likely,  with  statistical  power  increasing  simply  because  
the  random  between-­patient  variation  is  eliminated.  
  
Probe	  and	  position	   Adjusted	  p-­‐value	  
cg09489894_chr1-­‐248627123	   4.51E-­‐05	  
cg01259145_chr1-­‐202011187	   1.16E-­‐06	  
cg02184606_chr1-­‐202160116	   3.80E-­‐07	  
cg05772390_chr2-­‐136382578	   8.48E-­‐06	  
cg08556894_chr3-­‐52282218	   2.22E-­‐06	  
cg03598297_chr3-­‐4983076	   0.000269799	  
cg00248115_chr3-­‐65937365	   4.36E-­‐06	  
cg01314252_chr3-­‐9902144	   9.81E-­‐07	  
cg02082674_chr3-­‐51686759	   3.27E-­‐06	  
cg06768993_chr4-­‐8441685	   3.04E-­‐05	  
cg07481320_chr6-­‐42771284	   1.48E-­‐05	  
cg07222863_chr8-­‐103141365	   2.60E-­‐06	  
cg19827883_chr9-­‐97993198	   1.84E-­‐07	  
cg16260696_chr11-­‐67403729	   7.15E-­‐07	  
cg21777700_chr12-­‐116325396	   2.49E-­‐05	  
cg14533732_chr15-­‐76312477	   0.000314986	  
cg25534244_chr17-­‐55263738	   7.59E-­‐06	  
cg03195881_chr17-­‐77441759	   1.29E-­‐06	  
cg00911290_chr19-­‐10339685	   0.000673586	  
cg17518965_chr19-­‐3178958	   1.28E-­‐05	  
cg26680502_chr20-­‐38805123	   6.52E-­‐06	  
cg11509179_chr22-­‐30207156	   6.50E-­‐08	  
cg12435154_chr22-­‐37627667	   4.31E-­‐06	  
cg02237342_chr22-­‐24427552	   1.64E-­‐07	  
cg00017461_chr22-­‐30267328	   0.000313157	  
cg04163216_chr1-­‐9717812	   0.000224196	  
cg25534244_chr3-­‐52282218	   2.22E-­‐06	  
cg27082467_chr6-­‐25042281	   2.18E-­‐06	  
cg13656001_chr6-­‐25041715	   3.35E-­‐06	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Appendix 4: Adjusted p-values obtained from a Wilcoxon  signed  rank  test  
between  cfDNA  from  healthy  plasma  and  tumour  samples.  21  CpG  sites  
were  significant  with  an  alpha  level  of  0.05.  Not  significant  p-­values  are  
highlighted  in  red. 
 
Probe	   Adjusted	  p-­‐values	  
cg09489894_chr1-­‐248627123	   0.04329	  
cg01259145_chr1-­‐202011187	   0.04329	  
cg02184606_chr1-­‐202160116	   0.20979	  
cg05772390_chr2-­‐136382578	   0.04329	  
cg08556894_chr3-­‐52282218	   0.020979	  
cg03598297_chr3-­‐4983076	   0.04329	  
cg00248115_chr3-­‐65937365	   0.034965	  
cg01314252_chr3-­‐9902144	   0.04329	  
cg02082674_chr3-­‐51686759	   0.020979	  
cg06768993_chr4-­‐8441685	   0.397103	  
cg07481320_chr6-­‐42771284	   0.397103	  
cg07222863_chr8-­‐103141365	   0.20979	  
cg19827883_chr9-­‐97993198	   0.020979	  
cg16260696_chr11-­‐67403729	   0.020979	  
cg21777700_chr12-­‐116325396	   0.20979	  
cg14533732_chr15-­‐76312477	   0.20979	  
cg25534244_chr17-­‐55263738	   0.020979	  
cg03195881_chr17-­‐77441759	   0.152575	  
cg00911290_chr19-­‐10339685	   0.04329	  
cg17518965_chr19-­‐3178958	   1	  
cg26680502_chr20-­‐38805123	   0.020979	  
cg11509179_chr22-­‐30207156	   0.04329	  
cg12435154_chr22-­‐37627667	   0.020979	  
cg02237342_chr22-­‐24427552	   0.484688	  
cg00017461_chr22-­‐30267328	   0.04329	  
cg04163216_chr1-­‐9717812	   0.034965	  
cg25534244_chr3-­‐52282280	   0.04329	  
cg27082467_chr6-­‐25042281	   0.020979	  
cg13656001_chr6-­‐25041715	   0.020979	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Appendix  5:  Adjusted p-values obtained for a Wilcoxon  signed  rank  test  
between  cfDNA  from  healthy  plasma  and  leucocyte  samples.  Any  of  the  30  
CpG  sites  across  the  genome  were  differentially  methylated. 
 
  
Probe	   Adjusted	  p-­‐values	  
cg09489894_chr1-­‐248627123	   0.210909091	  
cg01259145_chr1-­‐202011187	   0.210909091	  
cg02184606_chr1-­‐202160116	   1	  
cg05772390_chr2-­‐136382578	   0.527272727	  
cg08556894_chr3-­‐52282218	   0.365875447	  
cg03598297_chr3-­‐4983076	   0.210909091	  
cg00248115_chr3-­‐65937365	   0.98018648	  
cg01314252_chr3-­‐9902144	   0.878787879	  
cg02082674_chr3-­‐51686759	   0.98018648	  
cg06768993_chr4-­‐8441685	   1	  
cg07481320_chr6-­‐42771284	   1	  
cg07222863_chr8-­‐103141365	   0.585858586	  
cg19827883_chr9-­‐97993198	   0.98018648	  
cg16260696_chr11-­‐67403729	   0.98018648	  
cg21777700_chr12-­‐116325396	   0.98018648	  
cg14533732_chr15-­‐76312477	   0.878787879	  
cg25534244_chr17-­‐55263738	   0.210909091	  
cg03195881_chr17-­‐77441759	   0.692890443	  
cg00911290_chr19-­‐10339685	   0.98018648	  
cg17518965_chr19-­‐3178958	   0.210909091	  
cg26680502_chr20-­‐38805123	   0.878787879	  
cg11509179_chr22-­‐30207156	   0.502164502	  
cg12435154_chr22-­‐37627667	   0.502164502	  
cg02237342_chr22-­‐24427552	   0.692890443	  
cg00017461_chr22-­‐30267328	   1	  
cg04163216_chr1-­‐9717812	   1	  
cg25534244_chr3-­‐52282280	   0.878787879	  
cg27082467_chr6-­‐25042281	   0.98018648	  
cg13656001_chr6-­‐25041715	   0.978198272	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Appendix   6:   Table   summarizing   primers   names,   primer   identifiers   (IDs)  





Primer  ID   Primer  forward   Primer  reverse  
3.1   cg09471455   AATTTGAGGTATTTTAGGTTTGG   CTCACAATTTCCTATTCCTACCTTAAAACC  
8.1   cg17698295   GTTGTTTGGTGGGGAGGGGATTG   CTCACACAACCTCCTAAACCC  
2.2   cg18081940   GTGTTTTATTGAGTAGAGAGTTTTTTTTTG   AACCACAACCTCTACCCTACC  
3.2   cg09471455   TGGGTTTTAAAGATGGTTTGGG   AATAAAACTATCAACCCCTCAATCCTC  
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Appendix  7:  Linear  regressions  showing  the  relationships  in  methylation  
measurements   (%)   between   EPIC   and   Fluidigm-­MiSeq.   30   CpGs   in   both  
tumour  and   leucocyte  paired  samples  profiled   in  both  platforms  passed  all   the  
filtering   criteria.   Pearson’s   correlation   coefficients   (r)   for   leucocyte   samples  
(blue   dots)   showed   a   greater   positive   correlation   between   both   platforms  










































































Appendix   8   :   Differential  
Methylation   for   122   CpG   sites  
obtained   across   across   all   48  
amplicons   assayed   on   Fluidigm  
Access  Array.  CpG  sites  within  the  
same   amplicon   showed   similar  
methylation   levels.   Probes   and  
genomic  positions  for  each  targeted  
CpG   on   GRCh38/hg38   Human  
Genome  are  provided.  The  majority  
of   tumour   samples   (red   dots)  
showed   clear   differences   in  
methylation  compared  to  leucocytes  
(blue   dots)   and   cfDNA   samples  
(black  dots)  
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Appendix 9: Adjusted p-values obtained from a Wilcoxon  signed  rank  test  
between  paired  tumour  and  leucocyte  samples.  All  CpG  sites  were  
significant  with  an  alpha  level  of  0.05.   
  
  













































































































MRes in Genomics and Experimental Medicine The University of Edinburgh 
 
102 
cg00911290_chr19-10339699 8,74E+09 
cg09034874_chr20-36646312 0.0012513425335745 
cg26680502_chr20-38805082 1,34E+08 
cg26680502_chr20-38805089 2,06E+09 
cg26680502_chr20-38805103 9,76E+08 
cg26680502_chr20-38805123 1,42E+09 
cg02237342_chr22-24427488 2,90E+08 
cg02237342_chr22-24427507 2,76E+08 
cg02237342_chr22-24427542 1,65E+08 
cg02237342_chr22-24427547 1,87E+08 
cg02237342_chr22-24427552 1,87E+08 
cg11509179_chr22-30207152 2,56E+07 
cg11509179_chr22-30207156 1,65E+08 
cg00017461_chr22-30267301 0.000421607029616094 
cg00017461_chr22-30267304 0.000496789543845604 
cg00017461_chr22-30267328 0.000376747488990707 
cg00017461_chr22-30267338 0.00318520223052771 
cg00017461_chr22-30267361 0.000593193935958368 
cg00017461_chr22-30267377 0.00375151359264498 
cg12435154_chr22-37627667 1,11E+09 
cg12435154_chr22-37627678 5,62E+08 
cg12435154_chr22-37627693 1,18E+09 
  
